[go: up one dir, main page]

US20060188447A1 - Process for the production of an abuse-proofed dosage form - Google Patents

Process for the production of an abuse-proofed dosage form Download PDF

Info

Publication number
US20060188447A1
US20060188447A1 US11/348,276 US34827606A US2006188447A1 US 20060188447 A1 US20060188447 A1 US 20060188447A1 US 34827606 A US34827606 A US 34827606A US 2006188447 A1 US2006188447 A1 US 2006188447A1
Authority
US
United States
Prior art keywords
dosage form
process according
abuse
portions
dried
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/348,276
Other languages
English (en)
Inventor
Elisabeth Arkenau-Maric
Johannes Bartholomaus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Assigned to GRUNENTHAL GMBH reassignment GRUNENTHAL GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ARKENAU-MARIC, ELISABETH DR., BARTHOLOMAUS, JOHANNES DR.
Publication of US20060188447A1 publication Critical patent/US20060188447A1/en
Priority to US12/140,609 priority Critical patent/US20080311197A1/en
Assigned to JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT reassignment JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS (EXCLUSIVELY LICENSED PATENTS) Assignors: ENDO PHARMACEUTICALS INC.
Assigned to MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT reassignment MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS Assignors: ENDO PHARMACEUTICALS INC.
Assigned to ENDO PHARMACEUTICALS INC. reassignment ENDO PHARMACEUTICALS INC. RELEASE OF SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS RECORDED AT REEL/FRAME 25456/172 Assignors: JPMORGAN CHASE BANK N.A., AS ADMINISTRATIVE AGENT
Assigned to ENDO PHARMACEUTICALS SOLUTIONS INC. reassignment ENDO PHARMACEUTICALS SOLUTIONS INC. RELEASE OF PATENT SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS Assignors: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
Assigned to ENDO PHARMACEUTICALS INC. reassignment ENDO PHARMACEUTICALS INC. CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF RECEIVING PARTY IN RELEASE OF PATENT SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS PREVIOUSLY RECORDED ON REEL 032380 FRAME 0157. ASSIGNOR(S) HEREBY CONFIRMS THE RELEASE OF SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS.. Assignors: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
Priority to US14/564,188 priority patent/US20150091201A1/en
Priority to US14/745,661 priority patent/US20150283086A1/en
Priority to US15/255,218 priority patent/US20160367485A1/en
Priority to US15/255,312 priority patent/US10729658B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Definitions

  • Active ingredients preferably pharmaceutical active ingredients with potential for abuse are known to the person skilled in the art, as are the quantities thereof to be used and processes for the production thereof, and may be present in the dosage form produced according to the invention as such, in the form of the corresponding derivatives thereof, in particular esters, ethers or amides, or in each case in the form of corresponding physiologically acceptable compounds, in particular in the form of the corresponding salts or solvates thereof, as racemates or stereoisomers.
  • the dosage form produced according to the invention may contain two or more pharmaceutical active ingredients.
  • the dosage form produced according to the invention preferably contains only one specific active ingredient.
  • Component (C) is preferably used in a quantity of 20 to 99.9 wt. %, particularly preferably of at least 30 wt. %, very particularly preferably of at least 40 wt. %, relative to the total weight the dosage form.
  • the process according to the invention may here be performed continuously or discontinuously.
  • the dosage form obtained according to the invention may comprise all of components (a)-(f).
  • substances which irritate the nasal passages and/or pharynx which may be considered according to the invention are any substances which, when administered accordingly via the nasal passages and/or pharynx, bring about a physical reaction which is either so unpleasant for the abuser that he/she does not wish to or cannot continue administration, for example burning, or physiologically counteracts taking of the corresponding active ingredient, for example due to increased nasal secretion or sneezing.
  • substances which conventionally irritate the nasal passages and/or pharynx may also bring about a very unpleasant sensation or even unbearable pain when administered parenterally, in particular intravenously, such that the abuser does not wish to or cannot continue taking the substance.
  • the substance which irritates the nasal passages and/or pharynx of component (a) is preferably based on one or more constituents or one or more plant parts of at least one hot substance drug.
  • Suitable antagonists for preventing abuse of the active ingredients are known per se to the person skilled in the art and may be present in the dosage form according to the invention as such or in the form of corresponding derivatives, in particular esters or ethers, or in each case in the form of corresponding physiologically acceptable compounds, in particular in the form of the salts or solvates thereof.
  • the dosage form obtained according to the invention preferably comprises these antagonists in a conventional therapeutic dose known to the person skilled in the art, particularly preferably in a quantity of twice to three times the conventional dose per administration unit.
  • component (f) as an additional abuse-preventing auxiliary substance, this addition of at least one bitter substance and the consequent impairment of the flavour of the dosage form additionally prevents oral and/or nasal abuse
  • the solid dosage form obtained according to the invention is suitable not only for oral, but also for vaginal or rectal administration, but is preferably for oral intake.
  • the dosage form is preferably not in film form.
  • the dosage form according to the invention may assume multiparticulate form, preferably cylindrical form, the form of microtablets, microcapsules, micropellets, granules, spheroids, beads or pellets, optionally packaged in capsules or press-moulded into tablets, preferably for oral administration.
  • the multiparticulate forms preferably have a size or size distribution in the range from 0.1 to 3 mm, particularly preferably in the range from 0.5 to 2 mm.
  • conventional auxiliary substances (B) are optionally also used for the formulation of the dosage form.
  • the dosage form produced according to the invention may comprise, between one layer of the subunit (X) and one layer of the subunit (Y), in each case one or more, preferably one, optionally swellable separation layer (Z) which serves to separate subunit (X) spatially from (Y).
  • auxiliary substances of the subunit(s) (X) or (Y) and of the optionally present separation layer(s) (Z) and/or of the barrier layer(s) (Z′) used in the formulation according to the invention of the dosage form will vary as a function of the arrangement thereof in the dosage form, the mode of administration and as a function of the particular active ingredient of the optionally present components (a) and/or (b) and/or (e) and of component (c) and/or (d) and/or (f).
  • the materials which have the requisite properties are in each case known per se to the person skilled in the art.
  • hydrophobic materials which are known to the person skilled in the art may be used as matrix materials.
  • Polymers particularly preferably cellulose ethers, cellulose esters and/or acrylic resins are preferably used as hydrophilic matrix materials.
  • Ethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxymethylcellulose, poly(meth)acrylic acid and/or the derivatives thereof, such as the salts, amides or esters thereof are very particularly preferably used as matrix materials.
  • Component (C) and the optionally present component (D), which serve to achieve the breaking strength of at least 500 N which is necessary according to the invention, may furthermore themselves serve as additional matrix materials.
  • FIG. 1 shows the measurement of the breaking strength of a tablet, in particular the tablet ( 4 ) adjustment device ( 6 ) used for this purpose before and during the measurement.
  • the tablet ( 4 ) is held between the upper pressure plate ( 1 ) and the lower pressure plate ( 3 ) of the force application apparatus (not shown) with the assistance of two 2-part clamping devices, which are in each case firmly fastened (not shown) with the upper and lower pressure plate once the spacing ( 5 ) necessary for accommodating and centring the tablet to be measured has been established.
  • the spacing ( 5 ) may be established by moving the 2-part clamping devices horizontally outwards or inwards in each case on the pressure plate on which they are mounted.
  • the tablets deemed to be resistant to breaking under a specific load include not only those which have not broken but also those which may have suffered plastic deformation under the action of the force.
  • the breaking strength of the tablets was determined using the above-described method. No breakage occurred when a force of 500 N was applied. The tablets could not be comminuted using a hammer, nor with the assistance of a pestle and mortar.
  • the breaking strength of the tablets was determined using the above-stated method. No breakage occurred when a force of 500 N was applied. The tablet could not be comminuted using a hammer, nor with the assistance of a pestle and mortar.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US11/348,276 2005-02-04 2006-02-06 Process for the production of an abuse-proofed dosage form Abandoned US20060188447A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US12/140,609 US20080311197A1 (en) 2005-02-04 2008-06-17 Process for the production of an abuse-proofed dosage form
US14/564,188 US20150091201A1 (en) 2005-02-04 2014-12-09 Process for the production of an abuse-proofed dosage form
US14/745,661 US20150283086A1 (en) 2005-02-04 2015-06-22 Process for the production of an abuse-proofed dosage form
US15/255,312 US10729658B2 (en) 2005-02-04 2016-09-02 Process for the production of an abuse-proofed dosage form
US15/255,218 US20160367485A1 (en) 2005-02-04 2016-09-02 Process for the production of an abuse-proofed dosage form

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005005449A DE102005005449A1 (de) 2005-02-04 2005-02-04 Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005449.8 2005-02-04

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/140,609 Division US20080311197A1 (en) 2005-02-04 2008-06-17 Process for the production of an abuse-proofed dosage form
US14/564,188 Continuation US20150091201A1 (en) 2005-02-04 2014-12-09 Process for the production of an abuse-proofed dosage form

Publications (1)

Publication Number Publication Date
US20060188447A1 true US20060188447A1 (en) 2006-08-24

Family

ID=36218706

Family Applications (6)

Application Number Title Priority Date Filing Date
US11/348,276 Abandoned US20060188447A1 (en) 2005-02-04 2006-02-06 Process for the production of an abuse-proofed dosage form
US12/140,609 Abandoned US20080311197A1 (en) 2005-02-04 2008-06-17 Process for the production of an abuse-proofed dosage form
US14/564,188 Abandoned US20150091201A1 (en) 2005-02-04 2014-12-09 Process for the production of an abuse-proofed dosage form
US14/745,661 Abandoned US20150283086A1 (en) 2005-02-04 2015-06-22 Process for the production of an abuse-proofed dosage form
US15/255,218 Abandoned US20160367485A1 (en) 2005-02-04 2016-09-02 Process for the production of an abuse-proofed dosage form
US15/255,312 Active US10729658B2 (en) 2005-02-04 2016-09-02 Process for the production of an abuse-proofed dosage form

Family Applications After (5)

Application Number Title Priority Date Filing Date
US12/140,609 Abandoned US20080311197A1 (en) 2005-02-04 2008-06-17 Process for the production of an abuse-proofed dosage form
US14/564,188 Abandoned US20150091201A1 (en) 2005-02-04 2014-12-09 Process for the production of an abuse-proofed dosage form
US14/745,661 Abandoned US20150283086A1 (en) 2005-02-04 2015-06-22 Process for the production of an abuse-proofed dosage form
US15/255,218 Abandoned US20160367485A1 (en) 2005-02-04 2016-09-02 Process for the production of an abuse-proofed dosage form
US15/255,312 Active US10729658B2 (en) 2005-02-04 2016-09-02 Process for the production of an abuse-proofed dosage form

Country Status (11)

Country Link
US (6) US20060188447A1 (fr)
EP (1) EP1845955B1 (fr)
JP (1) JP5265201B2 (fr)
CN (1) CN101111232B (fr)
AR (1) AR054222A1 (fr)
CA (1) CA2595979A1 (fr)
DE (1) DE102005005449A1 (fr)
IL (1) IL185017A (fr)
PE (1) PE20061204A1 (fr)
TW (1) TWI449540B (fr)
WO (1) WO2006082097A1 (fr)

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050031546A1 (en) * 2003-08-06 2005-02-10 Johannes Bartholomaus Abuse-proffed dosage form
US20080020032A1 (en) * 2006-07-21 2008-01-24 Michael Crowley Hydrophobic abuse deterrent delivery system for hydromorphone
WO2008033523A1 (fr) 2006-09-15 2008-03-20 Cima Labs Inc. Préparation médicamenteuse empêchant l'utilisation abusive
US20080280975A1 (en) * 2005-11-02 2008-11-13 Theraquest Biosciences, Inc. Methods of preventing the serotonin syndrome and compositions for use thereof
US20090082466A1 (en) * 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
US20100210732A1 (en) * 2005-11-02 2010-08-19 Najib Babul Methods of Preventing the Serotonin Syndrome and Compositions for Use Therefor
US20100249045A1 (en) * 2005-11-02 2010-09-30 Theraquest Biosciences, Inc. Multimodal Abuse Resistant and Extended Release Opioid Formulations
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US8114384B2 (en) 2004-07-01 2012-02-14 Gruenenthal Gmbh Process for the production of an abuse-proofed solid dosage form
US8192722B2 (en) 2003-08-06 2012-06-05 Grunenthal Gmbh Abuse-proof dosage form
WO2012085657A2 (fr) 2010-12-23 2012-06-28 Purdue Pharma L.P. Formes pharmaceutiques solides à usage oral résistant à la contrefaçon
US8337888B2 (en) 2001-08-06 2012-12-25 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US8383152B2 (en) 2008-01-25 2013-02-26 Gruenenthal Gmbh Pharmaceutical dosage form
US20140070453A1 (en) * 2011-05-03 2014-03-13 Shl Group Ab Mold Assembly and Method for Manufacturing a Syringe Container
US8722086B2 (en) 2007-03-07 2014-05-13 Gruenenthal Gmbh Dosage form with impeded abuse
US8808740B2 (en) 2010-12-22 2014-08-19 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US9005660B2 (en) 2009-02-06 2015-04-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
US9023394B2 (en) 2009-06-24 2015-05-05 Egalet Ltd. Formulations and methods for the controlled release of active drug substances
US9149533B2 (en) 2013-02-05 2015-10-06 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9161917B2 (en) 2008-05-09 2015-10-20 Grünenthal GmbH Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet
US9486413B2 (en) 2006-08-25 2016-11-08 Purdue Pharma L.P. Tamper resistant dosage forms
US9579285B2 (en) 2010-02-03 2017-02-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
US9616030B2 (en) 2013-03-15 2017-04-11 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9636303B2 (en) 2010-09-02 2017-05-02 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
US9642809B2 (en) 2007-06-04 2017-05-09 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
US9655853B2 (en) 2012-02-28 2017-05-23 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
US9675610B2 (en) 2002-06-17 2017-06-13 Grünenthal GmbH Abuse-proofed dosage form
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
US9855263B2 (en) 2015-04-24 2018-01-02 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
US9913814B2 (en) 2014-05-12 2018-03-13 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9925146B2 (en) 2009-07-22 2018-03-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
US10058548B2 (en) 2003-08-06 2018-08-28 Grünenthal GmbH Abuse-proofed dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US10080721B2 (en) 2009-07-22 2018-09-25 Gruenenthal Gmbh Hot-melt extruded pharmaceutical dosage form
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
US10201502B2 (en) 2011-07-29 2019-02-12 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
US10300141B2 (en) 2010-09-02 2019-05-28 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
US10335373B2 (en) 2012-04-18 2019-07-02 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10449547B2 (en) 2013-11-26 2019-10-22 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
US10525053B2 (en) 2002-07-05 2020-01-07 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
US10632201B2 (en) 2017-10-19 2020-04-28 Capsugel Belgium Nv Immediate release abuse deterrent formulations
US10646485B2 (en) 2016-06-23 2020-05-12 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US10695297B2 (en) 2011-07-29 2020-06-30 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
US10729658B2 (en) 2005-02-04 2020-08-04 Grünenthal GmbH Process for the production of an abuse-proofed dosage form
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US11224576B2 (en) 2003-12-24 2022-01-18 Grünenthal GmbH Process for the production of an abuse-proofed dosage form
US11844865B2 (en) 2004-07-01 2023-12-19 Grünenthal GmbH Abuse-proofed oral dosage form

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
DE102007025858A1 (de) 2007-06-01 2008-12-04 Grünenthal GmbH Verfahren zur Herstellung einer Arzneimitteldarreichungsform
DE102007039043A1 (de) 2007-08-17 2009-02-19 Grünenthal GmbH Sternverteiler
WO2011079074A1 (fr) * 2009-12-24 2011-06-30 Acura Phamaceuticals, Inc. Compositions pharmaceutiques pour prévenir un mauvaise usage, un usage abusif et un usage détourné
CN103179956A (zh) 2010-09-02 2013-06-26 格吕伦塔尔有限公司 包含阴离子聚合物的抗破碎剂型
AU2012320496C1 (en) 2011-10-06 2017-09-28 Grünenthal GmbH Tamper-resistant oral pharmaceutical dosage form comprising opioid agonist and opioid antagonist
BR112014011504A2 (pt) 2011-11-17 2017-05-09 Gruenenthal Gmbh forma de dosagem farmacêutica oral inviolável compreendendo ingrediente farmacologicamente ativo, antagonista opioide e/ou agente aversivo, óxido de polialquileno e polímero aniônico
US20130225625A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant pharmaceutical dosage form comprising nonionic surfactant
EA029171B1 (ru) 2012-05-11 2018-02-28 Грюненталь Гмбх Термоформованная устойчивая к разрушению фармацевтическая лекарственная форма, содержащая цинк, и способ ее получения
WO2014011830A1 (fr) 2012-07-12 2014-01-16 Mallinckrodt Llc Compositions pharmaceutiques de dissuasion d'abus à libération prolongée
ES2764445T3 (es) 2013-03-15 2020-06-03 Inspirion Delivery Sciences Llc Productos farmacéuticos que comprenden un componente dependiente de pH y un agente de aumento del pH
WO2015091352A1 (fr) 2013-12-16 2015-06-25 Grünenthal GmbH Forme galénique inviolable ayant un profil de libération bimodal et fabriqué par coextrusion
US10632113B2 (en) 2014-02-05 2020-04-28 Kashiv Biosciences, Llc Abuse-resistant drug formulations with built-in overdose protection
CA2975653A1 (fr) 2015-02-03 2016-08-11 Grunenthal Gmbh Forme pharmaceutique inviolable comprenant un copolymere greffe par polyethylene glycol
AU2016251853A1 (en) 2015-04-24 2017-11-23 Grünenthal GmbH Tamper-resistant fixed dose combination providing fast release of two drugs from different particles
JP2018513864A (ja) 2015-04-24 2018-05-31 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 粒子及びマトリックスから２種の薬物の急速放出をもたらすタンパレジスタントな固定用量組合せ
US20160310437A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant fixed dose combination providing fast release of two drugs from particles
US20170296476A1 (en) 2016-04-15 2017-10-19 Grünenthal GmbH Modified release abuse deterrent dosage forms
WO2018007507A1 (fr) 2016-07-06 2018-01-11 Grünenthal GmbH Forme posologique pharmaceutique renforcée
EP3490537A1 (fr) 2016-08-01 2019-06-05 Grünenthal GmbH Forme galénique inviolable comprenant un polysaccharide anionique
CA2941315C (fr) * 2016-08-12 2018-03-06 Api Labs Inc. Pavot a teneur elevee en thebaine et procede de fabrication associe
CA3033423A1 (fr) 2016-08-12 2018-02-15 Grunenthal Gmbh Formulation inviolable de l'ephedrine et de ses derives.
JP6131379B1 (ja) * 2016-12-28 2017-05-17 森下仁丹株式会社 ４，５−エポキシモルヒナン誘導体含有製剤
EP3438133A1 (fr) 2017-08-04 2019-02-06 Basell Polyolefine GmbH Processus de polymérisation comprenant des particules de polyoléfine de décharge provenant d'un réacteur de polymérisation en phase gazeuse
CA3078272A1 (fr) 2017-10-13 2019-04-18 Grunenthal Gmbh Formes posologiques a liberation modifiee, dissuasives d'abus
MX2020005438A (es) 2017-12-20 2020-12-03 Purdue Pharma Lp Formas de dosificacion de sulfato de morfina disuasivas del abuso.
TW202002957A (zh) 2018-02-09 2020-01-16 德商歌林達有限公司 包含轉化抑制劑之麻黃素及其衍生物之抗損壞調配物
EP3698776A1 (fr) 2019-02-19 2020-08-26 Grünenthal GmbH Forme posologique inviolable à libération immédiate et résistance à l'extraction par solvant
WO2021219577A1 (fr) 2020-04-27 2021-11-04 Grünenthal GmbH Forme posologique comprenant des comprimés extrudés à chaud contenant un copolymère eva et un agent de glissement
WO2021219576A1 (fr) 2020-04-27 2021-11-04 Grünenthal GmbH Forme posologique à particules multiples contenant un copolymère eva et un excipient supplémentaire

Citations (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652589A (en) * 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
US3865108A (en) * 1971-05-17 1975-02-11 Ortho Pharma Corp Expandable drug delivery device
US4002173A (en) * 1974-07-23 1977-01-11 International Paper Company Diester crosslinked polyglucan hydrogels and reticulated sponges thereof
US4014965A (en) * 1972-11-24 1977-03-29 The Dow Chemical Company Process for scrapless forming of plastic articles
US4070497A (en) * 1971-03-09 1978-01-24 Ppg Industries, Inc. Process of applying and curing a plurality of coatings
US4070494A (en) * 1975-07-09 1978-01-24 Bayer Aktiengesellschaft Enteral pharmaceutical compositions
US4200704A (en) * 1978-09-28 1980-04-29 Union Carbide Corporation Controlled degradation of poly(ethylene oxide)
US4262017A (en) * 1978-05-22 1981-04-14 Basf Aktiengesellschaft Preparation of a vitamin E dry powder
US4427778A (en) * 1982-06-29 1984-01-24 Biochem Technology, Inc. Enzymatic preparation of particulate cellulose for tablet making
US4427681A (en) * 1982-09-16 1984-01-24 Richardson-Vicks, Inc. Thixotropic compositions easily convertible to pourable liquids
US4892889A (en) * 1986-11-18 1990-01-09 Basf Corporation Process for making a spray-dried, directly-compressible vitamin powder comprising unhydrolyzed gelatin
US4992279A (en) * 1985-07-03 1991-02-12 Kraft General Foods, Inc. Sweetness inhibitor
US4992278A (en) * 1987-01-14 1991-02-12 Ciba-Geigy Corporation Therapeutic system for sparingly soluble active ingredients
US5082668A (en) * 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US5190760A (en) * 1989-07-08 1993-03-02 Coopers Animal Health Limited Solid pharmaceutical composition
US5198226A (en) * 1986-01-30 1993-03-30 Syntex (U.S.A.) Inc. Long acting nicardipine hydrochloride formulation
US5378462A (en) * 1992-08-19 1995-01-03 Kali-Chemie Pharma Gmbh Pancreatin micropellets prepared with polyethylene glycol 4000, paraffin and a lower alcohol by extrusion and rounding
US5387420A (en) * 1988-08-26 1995-02-07 May & Baker Ltd. Morphine-containing efferverscent composition
US5508042A (en) * 1991-11-27 1996-04-16 Euro-Celtigue, S.A. Controlled release oxycodone compositions
US5591452A (en) * 1993-05-10 1997-01-07 Euro-Celtique, S.A. Controlled release formulation
US5593694A (en) * 1991-10-04 1997-01-14 Yoshitomi Pharmaceutical Industries, Ltd. Sustained release tablet
US5601842A (en) * 1993-09-03 1997-02-11 Gruenenthal Gmbh Sustained release drug formulation containing a tramadol salt
US5620697A (en) * 1992-12-31 1997-04-15 Orion-Yhtyma Oy Method for preparing matrix-type pharmaceutical compositions through ultrasonic means to accomplish melting
US5707636A (en) * 1994-08-03 1998-01-13 Saitec S.R.L. Apparatus and method for preparing solid forms with controlled release of the active ingredient
US5741519A (en) * 1995-03-21 1998-04-21 Basf Aktiengesellschaft The production of active substance compositions in the form of a solid solution of the active substance in a polymer matrix, and active substance compositions produced by this process
US5866164A (en) * 1996-03-12 1999-02-02 Alza Corporation Composition and dosage form comprising opioid antagonist
US6009690A (en) * 1994-12-23 2000-01-04 Basf Aktiengesellschaft Process and apparatus for the production of divisible tablets
US6051253A (en) * 1996-07-23 2000-04-18 Basf Aktiengesellschaft Production of solid drug forms
US6183781B1 (en) * 1996-05-14 2001-02-06 Alkermes Controlled Therapeutics, Inc. Method for fabricating polymer-based controlled-release devices
US6337319B1 (en) * 1995-08-18 2002-01-08 Wuyi Wang μ-Selective opioid peptides
US20020012701A1 (en) * 2000-06-19 2002-01-31 Karl Kolter Process for producing solid oral dosage forms with sustained release of active ingredient
US6344535B1 (en) * 1997-12-03 2002-02-05 Bayer Aktiengesellschaft Polyether ester amides
US20020015730A1 (en) * 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
US6348469B1 (en) * 1995-04-14 2002-02-19 Pharma Pass Llc Solid compositions containing glipizide and polyethylene oxide
US6355656B1 (en) * 1995-12-04 2002-03-12 Celgene Corporation Phenidate drug formulations having diminished abuse potential
US6375963B1 (en) * 1999-06-16 2002-04-23 Michael A. Repka Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US20030008409A1 (en) * 2001-07-03 2003-01-09 Spearman Steven R. Method and apparatus for determining sunlight exposure
US20030015814A1 (en) * 1999-12-15 2003-01-23 Harald Krull Device and method for producing solid shape containing an active ingredient
US20030017532A1 (en) * 1998-09-22 2003-01-23 Sanjoy Biswas ndp
US20030031546A1 (en) * 2001-08-08 2003-02-13 Toshiyuki Araki Lift apparatus
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030068276A1 (en) * 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
US20030068370A1 (en) * 2001-08-06 2003-04-10 Richard Sackler Pharmaceutical formulation containing irritant
US20030068392A1 (en) * 2001-08-06 2003-04-10 Richard Sackler Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US20030069263A1 (en) * 2001-07-18 2003-04-10 Breder Christopher D. Pharmaceutical combinations of oxycodone and naloxone
US20030068375A1 (en) * 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030068371A1 (en) * 2001-08-06 2003-04-10 Benjamin Oshlack Pharmaceutical formulation containing opioid agonist,opioid antagonist and gelling agent
US6547997B1 (en) * 1997-11-28 2003-04-15 Abbot Laboratories Method for producing solvent-free noncrystalline biologically active substances
US6547977B1 (en) * 1998-04-02 2003-04-15 Applied Materials Inc. Method for etching low k dielectrics
US20030077297A1 (en) * 1999-02-26 2003-04-24 Feng-Jing Chen Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20040011806A1 (en) * 2002-07-17 2004-01-22 Luciano Packaging Technologies, Inc. Tablet filler device with star wheel
US20040052731A1 (en) * 2002-07-05 2004-03-18 Collegium Pharmaceuticals, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US20040052844A1 (en) * 2002-09-16 2004-03-18 Fang-Hsiung Hsiao Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
US6723343B2 (en) * 1999-08-31 2004-04-20 Gruenenthal Gmbh Pharmaceutical tramadol salts
US20040081694A1 (en) * 1994-11-04 2004-04-29 Euro-Celtique, S.A. Melt-extruded orally administrable opioid formulations
US20050015730A1 (en) * 2003-07-14 2005-01-20 Srimanth Gunturi Systems, methods and computer program products for identifying tab order sequence of graphically represented elements
US20050031546A1 (en) * 2003-08-06 2005-02-10 Johannes Bartholomaus Abuse-proffed dosage form
US20050058706A1 (en) * 2001-10-24 2005-03-17 Grunenthal Gmbh Delayed release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol
US20050063214A1 (en) * 2003-09-22 2005-03-24 Daisaburo Takashima Semiconductor integrated circuit device
US20050089475A1 (en) * 2001-08-06 2005-04-28 Thomas Gruber Pharmaceutical formulation containing dye
US20060002860A1 (en) * 2004-07-01 2006-01-05 Johannes Bartholomaus Abuse-proofed oral dosage form
US20060002859A1 (en) * 2004-07-01 2006-01-05 Elisabeth Arkenau Process for production of an abuse-proofed solid dosage form
US20060004034A1 (en) * 2002-11-11 2006-01-05 Gruenenthal Gmbh Spirocyclic cyclohexane compounds
US20060009478A1 (en) * 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain
US20060017916A1 (en) * 2004-06-09 2006-01-26 Clarke Allan J Apparatus for producing a pharmaceutical product
US20060039864A1 (en) * 2004-07-01 2006-02-23 Johannes Bartholomaus Abuse-proofed oral dosage form
US20070003616A1 (en) * 2003-12-24 2007-01-04 Elisabeth Arkenau-Maric Process for the production of an abuse-proofed dosage form
US7176251B1 (en) * 1996-11-05 2007-02-13 Novamont S.P.A. Biodegradable polymeric compositions comprising starch and a thermoplastic polymer
US20070065365A1 (en) * 2004-04-21 2007-03-22 Gruenenthal Gmbh Abuse-resistant transdermal system
US7201920B2 (en) * 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
USRE39593E1 (en) * 1994-07-23 2007-04-24 Gruenenthal Gmbh 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects
US20080069871A1 (en) * 2006-07-21 2008-03-20 Vaughn Jason M Hydrophobic abuse deterrent delivery system
US20080081290A1 (en) * 2006-09-25 2008-04-03 Fujifilm Corporation Resist composition, resin for use in the resist composition, compound for use in the synthesis of the resin, and pattern-forming method using the resist composition
US20090004267A1 (en) * 2007-03-07 2009-01-01 Gruenenthal Gmbh Dosage Form with Impeded Abuse
US20090011016A1 (en) * 2006-03-01 2009-01-08 Ethypharm Sa Crush-Resistant Oxycodone Tablets Intended For Preventing Accidental Misuse And Unlawful Diversion
US20090017121A1 (en) * 2001-10-25 2009-01-15 Bret Berner Gastric retained gabapentin dosage form
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
US20090081290A1 (en) * 2006-08-25 2009-03-26 Purdue Pharma L.P. Tamper resistant dosage forms
US7674799B2 (en) * 2004-03-30 2010-03-09 Purdue Pharma L.P. Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
US20100092553A1 (en) * 2005-11-10 2010-04-15 Flamel Technologies anti-misuse microparticulate oral pharmaceutical form
US20100104638A1 (en) * 2008-10-27 2010-04-29 Wei-Guo Dai Extended release oral acetaminophen/tramadol dosage form
US20110020454A1 (en) * 2008-03-13 2011-01-27 Rosa Lamarca Casado Novel dosage and formulation
US20110092515A1 (en) * 2008-07-03 2011-04-21 Zhihui Qiu Melt granulation process
US20110097404A1 (en) * 2000-02-08 2011-04-28 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US20120034171A1 (en) * 2003-08-06 2012-02-09 Gruenenthal Gmbh Abuse-proofed dosage form
US20120059065A1 (en) * 2010-09-02 2012-03-08 Grünenthal GmbH Tamper Resistant Dosage Form Comprising An Anionic Polymer
US20120065220A1 (en) * 2010-09-02 2012-03-15 Grunenthal Gmbh Tamper Resistant Dosage Form Comprising An Anionic Polymer
US20130028970A1 (en) * 2011-07-29 2013-01-31 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
US8383152B2 (en) * 2008-01-25 2013-02-26 Gruenenthal Gmbh Pharmaceutical dosage form

Family Cites Families (487)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2524855A (en) 1950-10-10 Process for the manufacture of
CA722109A (en) 1965-11-23 W. Mock Henry Extrusion of ethylene oxide polymers
US2806033A (en) 1955-08-03 1957-09-10 Lewenstein Morphine derivative
US2987445A (en) 1958-10-10 1961-06-06 Rohm & Haas Drug composition
US3370035A (en) 1961-06-23 1968-02-20 Takeda Chemical Industries Ltd Stabilization of polyalkylene oxide
US3332950A (en) 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives
GB1147210A (en) 1965-06-30 1969-04-02 Eastman Kodak Co Improvements in or relating to vitamins
US3806603A (en) * 1969-10-13 1974-04-23 W Gaunt Pharmaceutical carriers of plasticized dried milled particles of hydrated cooked rice endosperm
CH503520A (de) 1969-12-15 1971-02-28 Inventa Ag Verfahren zum Vermahlen von körnigen Materialien, insbesondere von Kunststoffgranulaten, bei tiefen Temperaturen
US3966747A (en) 1972-10-26 1976-06-29 Bristol-Myers Company 9-Hydroxy-6,7-benzomorphans
US3980766A (en) 1973-08-13 1976-09-14 West Laboratories, Inc. Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US3941865A (en) 1973-12-10 1976-03-02 Union Carbide Corporation Extrusion of ethylene oxide resins
JPS603286B2 (ja) 1977-03-03 1985-01-26 日本化薬株式会社 定速溶出性製剤
US4207893A (en) 1977-08-29 1980-06-17 Alza Corporation Device using hydrophilic polymer for delivering drug to biological environment
US4175119A (en) 1978-01-11 1979-11-20 Porter Garry L Composition and method to prevent accidental and intentional overdosage with psychoactive drugs
US4211681A (en) 1978-08-16 1980-07-08 Union Carbide Corporation Poly(ethylene oxide) compositions
NO793297L (no) 1978-10-19 1980-04-22 Mallinckrodt Inc Fremgangsmaate til fremstilling av oksymorfon
US4215104A (en) 1979-03-26 1980-07-29 Mead Johnson & Company Multi-fractionable tablet structure
US4258027A (en) 1979-03-26 1981-03-24 Mead Johnson & Company Multi-fractionable tablet structure
CA1146866A (fr) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Procede de production d'un compose pharmaceutique a liberation continue sous forme solide
CH648754A5 (en) 1979-08-16 1985-04-15 Ciba Geigy Ag Pharmaceutical slow release tablet
US4353887A (en) 1979-08-16 1982-10-12 Ciba-Geigy Corporation Divisible tablet having controlled and delayed release of the active substance
US4457933A (en) 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
JPS56169622A (en) 1980-06-03 1981-12-26 Kissei Pharmaceut Co Ltd Method of making solid preparation from oily substance
DE3024416C2 (de) 1980-06-28 1982-04-15 Gödecke AG, 1000 Berlin Verfahren zur Herstellung von Arzneimitteln mit retardierter Wirkstoff-Freisetzung
US4473640A (en) 1982-06-03 1984-09-25 Combie Joan D Detection of morphine and its analogues using enzymatic hydrolysis
US4462941A (en) 1982-06-10 1984-07-31 The Regents Of The University Of California Dynorphin amide analogs
US4485211A (en) 1982-09-15 1984-11-27 The B. F. Goodrich Company Poly(glycidyl ether)block copolymers and process for their preparation
US4529583A (en) 1983-03-07 1985-07-16 Clear Lake Development Group Composition and method of immobilizing emetics and method of treating human beings with emetics
US4603143A (en) 1983-05-02 1986-07-29 Basf Corporation Free-flowing, high density, fat soluble vitamin powders with improved stability
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4599342A (en) 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4629621A (en) 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
AU592065B2 (en) 1984-10-09 1990-01-04 Dow Chemical Company, The Sustained release dosage form based on highly plasticized cellulose ether gels
GB8507779D0 (en) 1985-03-26 1985-05-01 Fujisawa Pharmaceutical Co Drug carrier
US4690814A (en) * 1985-06-17 1987-09-01 The Standard Oil Company Process for the production of hydrogen
DE3673789D1 (de) 1985-06-24 1990-10-04 Ici Australia Ltd Einnehmbare kapseln.
DE3689195T2 (de) 1985-06-28 1994-05-05 Carrington Lab Inc Verfahren zur Herstellung von Aloe-Erzeugnissen, Erzeugnisse und Zusammensetzungen dazu.
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
EP0226061B1 (fr) 1985-12-17 1994-02-16 United States Surgical Corporation Polymères biorésorbables de haut poids moléculaire et articles à base de ces polymères
US5229164A (en) * 1985-12-19 1993-07-20 Capsoid Pharma Gmbh Process for producing individually dosed administration forms
US4711894A (en) 1986-01-16 1987-12-08 Henkel Corporation Stabilized tocopherol in dry, particulate, free-flowing form
US4940556A (en) 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
US4764378A (en) 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
EP0239973A3 (en) 1986-03-31 1989-11-08 Union Carbide Corporation Catalyst and process for alkylene oxide polymerization
DE3612211A1 (de) 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
US4667013A (en) 1986-05-02 1987-05-19 Union Carbide Corporation Process for alkylene oxide polymerization
US4713243A (en) 1986-06-16 1987-12-15 Johnson & Johnson Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
USRE33093E (en) 1986-06-16 1989-10-17 Johnson & Johnson Consumer Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
USRE34990E (en) 1986-08-07 1995-07-04 Ciba-Geigy Corporation Oral therapeutic system having systemic action
CA1335748C (fr) 1986-09-25 1995-05-30 Jeffrey Lawrence Finnan Gelatines reticulees
US5227157A (en) 1986-10-14 1993-07-13 Board Of Regents, The University Of Texas System Delivery of therapeutic agents
WO1988003408A1 (fr) 1986-11-10 1988-05-19 Biopure Corporation Succedane du sang semi-synthetique extra pur
JPH0831303B2 (ja) 1986-12-01 1996-03-27 オムロン株式会社 チツプ型ヒユ−ズ
US4892778A (en) 1987-05-27 1990-01-09 Alza Corporation Juxtaposed laminated arrangement
US5051261A (en) 1987-11-24 1991-09-24 Fmc Corporation Method for preparing a solid sustained release form of a functionally active composition
JP2719020B2 (ja) 1987-12-17 1998-02-25 ジ・アップジョン・カンパニー 三本の溝付き錠剤
DE3812567A1 (de) 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
US4954346A (en) 1988-06-08 1990-09-04 Ciba-Geigy Corporation Orally administrable nifedipine solution in a solid light resistant dosage form
US4960814A (en) 1988-06-13 1990-10-02 Eastman Kodak Company Water-dispersible polymeric compositions
US5350741A (en) * 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
JPH0249719A (ja) 1988-08-11 1990-02-20 Dai Ichi Kogyo Seiyaku Co Ltd 易水分散・可溶性能を有する油溶性ビタミン粉末
DE3830353A1 (de) 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
US5004601A (en) 1988-10-14 1991-04-02 Zetachron, Inc. Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
US5139790A (en) 1988-10-14 1992-08-18 Zetachron, Inc. Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
US4957668A (en) 1988-12-07 1990-09-18 General Motors Corporation Ultrasonic compacting and bonding particles
US5169645A (en) 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
US5200197A (en) * 1989-11-16 1993-04-06 Alza Corporation Contraceptive pill
GB8926612D0 (en) 1989-11-24 1990-01-17 Erba Farmitalia Pharmaceutical compositions
EP0449775A3 (en) 1990-03-29 1992-09-02 Ciba-Geigy Ag Polyether-polyester block copolymers and their use as dispersing agents
SU1759445A1 (ru) 1990-06-15 1992-09-07 Ленинградский Технологический Институт Им.Ленсовета Способ получени капсулированных гидрофобных веществ
FR2664851B1 (fr) 1990-07-20 1992-10-16 Oreal Procede de compactage d'un melange pulverulent permettant d'obtenir un produit compact absorbant ou partiellement delitable et produit obtenu par ce procede.
EP0477135A1 (fr) 1990-09-07 1992-03-25 Warner-Lambert Company Microcapsules enduites sphéroidales mâchables et méthodes de leur préparation
US5126151A (en) 1991-01-24 1992-06-30 Warner-Lambert Company Encapsulation matrix
US5273758A (en) 1991-03-18 1993-12-28 Sandoz Ltd. Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms
US5149538A (en) 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
JP3073054B2 (ja) 1991-07-11 2000-08-07 住友精化株式会社 アルキレンオキシド重合体の製造方法
DE69231856T2 (de) 1991-08-30 2002-03-28 Showa Yakuhin Kako Co., Ltd. Trockene gelzusammensetzung
AU2670292A (en) 1991-10-04 1993-05-03 Olin Corporation Fungicide tablet
DE4138513A1 (de) 1991-11-23 1993-05-27 Basf Ag Feste pharmazeutische retardform
DE69212497T2 (de) 1991-12-05 1996-12-12 Mallinckrodt Veterinary, Inc., Mundelein, Ill. Glasartige kohlenhydratenmatrize zur verabreichung von heilmitteln mit verzögerter wirkstoffabgabe
US5200194A (en) 1991-12-18 1993-04-06 Alza Corporation Oral osmotic device
SG43179A1 (en) 1991-12-18 1997-10-17 Warner Lambert Co A process for the prepatation of a solid dispersion
US5225417A (en) 1992-01-21 1993-07-06 G. D. Searle & Co. Opioid agonist compounds
IL105553A (en) 1992-05-06 1998-01-04 Janssen Pharmaceutica Inc Solid dosage form comprising a porous network of matrix forming material which disperses rapidly in water
ES2086229T3 (es) 1992-05-22 1996-06-16 Goedecke Ag Procedimiento para la obtencion de preparados medicinales de accion retardada.
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
DE4229085C2 (de) 1992-09-01 1996-07-11 Boehringer Mannheim Gmbh Längliche, teilbare Tablette
NZ255579A (en) * 1992-09-18 1996-03-26 Yamanouchi Pharma Co Ltd Sustained release hydrogel pharmaceutical formulation
US5472943A (en) 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
FI101039B (fi) 1992-10-09 1998-04-15 Eeva Kristoffersson Menetelmä lääkepellettien valmistamiseksi
AU679937B2 (en) 1992-11-18 1997-07-17 Johnson & Johnson Consumer Products, Inc. Extrudable compositions for topical or transdermal drug delivery
ATE183641T1 (de) 1992-12-23 1999-09-15 Saitec Srl Verfahren zur herstellung von arzneiformen und kontrollierte freigabe und die soerhaltenen arzneiformen
US6071970A (en) 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US5914132A (en) 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
DE4309528C2 (de) 1993-03-24 1998-05-20 Doxa Gmbh Folie oder Folienschlauch aus Casein, Verfahren zu deren Herstellung und deren Verwendung
IL109944A (en) 1993-07-01 1998-12-06 Euro Celtique Sa Sustained release dosage unit forms containing morphine and a method of preparing these sustained release dosage unit forms
HU218673B (hu) 1993-10-07 2000-10-28 Euroceltique S.A. Opioid analgetikumot tartalmazó elnyújtott hatóanyag-felszabadítású orális gyógyszerkészítmény és eljárás előállítására
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
ES2168290T3 (es) 1993-11-23 2002-06-16 Euro Celtique Sa Metodo para preparar una composicion de liberacion sostenida.
WO1995017174A1 (fr) 1993-12-20 1995-06-29 The Procter & Gamble Company Procede de production de laxatifs contenant du sulfosuccinate de dioctyle
IL112106A0 (en) 1993-12-22 1995-03-15 Ergo Science Inc Accelerated release composition containing bromocriptine
GB9401894D0 (en) 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
MX9603480A (es) 1994-02-16 1997-12-31 Abbott Lab Procedimiento para preparar formulaciones farmaceuticas en particulas finas.
US5458887A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
DE4413350A1 (de) 1994-04-18 1995-10-19 Basf Ag Retard-Matrixpellets und Verfahren zu ihrer Herstellung
ES2163504T5 (es) 1994-05-06 2008-05-16 Pfizer Inc. Formas de dosificacion de liberacion controlada de azitromicina.
AT403988B (de) 1994-05-18 1998-07-27 Lannacher Heilmittel Festes orales retardpräparat
US5460826A (en) 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
JP3285452B2 (ja) 1994-08-11 2002-05-27 サンスター株式会社 歯磨組成物
US5837790A (en) 1994-10-24 1998-11-17 Amcol International Corporation Precipitation polymerization process for producing an oil adsorbent polymer capable of entrapping solid particles and liquids and the product thereof
AUPM897594A0 (en) 1994-10-25 1994-11-17 Daratech Pty Ltd Controlled release container
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
US5945125A (en) 1995-02-28 1999-08-31 Temple University Controlled release tablet
US6117453A (en) 1995-04-14 2000-09-12 Pharma Pass Solid compositions containing polyethylene oxide and an active ingredient
US5900425A (en) 1995-05-02 1999-05-04 Bayer Aktiengesellschaft Pharmaceutical preparations having controlled release of active compound and processes for their preparation
DE19522899C1 (de) 1995-06-23 1996-12-19 Hexal Pharmaforschung Gmbh Verfahren zum kontinuierlichen Ersintern eines Granulats
US5759583A (en) 1995-08-30 1998-06-02 Syntex (U.S.A.) Inc. Sustained release poly (lactic/glycolic) matrices
US6063405A (en) 1995-09-29 2000-05-16 L.A.M. Pharmaceuticals, Llc Sustained release delivery system
US5811126A (en) 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
DE19539361A1 (de) 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung
US5908850A (en) 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
DE19547766A1 (de) 1995-12-20 1997-06-26 Gruenenthal Gmbh 1-Phenyl-2-dimethylaminomethyl-cyclohexan-1-ol-verbindungen als pharmazeutische Wirkstoffe
US6461644B1 (en) * 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US20020114838A1 (en) * 1996-04-05 2002-08-22 Ayer Atul D. Uniform drug delivery therapy
KR19990087076A (ko) 1996-04-05 1999-12-15 다께다 구니오 안지오텐신 ⅱ 및 길항 활성을 갖는 화합물을 함유하는 약제학적 배합물
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
KR20000016331A (ko) 1996-06-06 2000-03-25 베제리브 니엘슨 경구 제제용 알긴산 함유 장용 코팅
DK1014941T3 (da) 1996-06-26 2009-07-27 Univ Texas Ekstruderbar farmaceutisk hot-melt-formulering
ES2322405T3 (es) 1996-07-08 2009-06-19 Penwest Pharmaceuticals Co. Matriz de liberacion controlada para farmacos insolubles en dosis elevadas.
NL1003684C2 (nl) 1996-07-25 1998-01-28 Weterings B V H Inrichting voor het afgeven van een vloeistof.
DE19630236A1 (de) 1996-07-26 1998-01-29 Wolff Walsrode Ag Biaxial gereckte, biologisch abbaubare und kompostierbare Wursthülle
BE1010353A5 (fr) 1996-08-14 1998-06-02 Boss Pharmaceuticals Ag Procede pour la fabrication de produits pharmaceutiques, dispositif pour un tel procede et produits pharmaceutiques ainsi obtenus.
US5991799A (en) 1996-12-20 1999-11-23 Liberate Technologies Information retrieval system using an internet multiplexer to focus user selection
DE19705538C1 (de) 1997-02-14 1998-08-27 Goedecke Ag Verfahren zur Trennung von Wirkstoffen in festen pharmazeutischen Zubereitungen
US5948787A (en) 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
DE19710008A1 (de) 1997-03-12 1998-09-17 Basf Ag Feste, mindestens zweiphasige Zubereitungsformen eines Opioid-Analgeticums mit verzögerter Freisetzung
DE19710009A1 (de) 1997-03-12 1998-09-24 Knoll Ag Mehrphasige wirkstoffhaltige Zubereitungsformen
DE19710213A1 (de) 1997-03-12 1998-09-17 Basf Ag Verfahren zur Herstellung von festen Kombinationsarzneiformen
US6139770A (en) 1997-05-16 2000-10-31 Chevron Chemical Company Llc Photoinitiators and oxygen scavenging compositions
DE19721467A1 (de) 1997-05-22 1998-11-26 Basf Ag Verfahren zur Herstellung kleinteiliger Zubereitungen biologisch aktiver Stoffe
CA2290624C (fr) * 1997-06-06 2006-12-05 John W. Shell Formes de dosage de medicaments administres par voie orale a retention gastrique pour liberation lente de medicaments hautement solubles
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
EP1009387B1 (fr) 1997-07-02 2006-04-12 Euro-Celtique S.A. Formulations de tramadol stabilisees a liberation prolongee
IE970588A1 (en) 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
JP2003525828A (ja) 1997-09-10 2003-09-02 アライドシグナル インコーポレイテッド ジルコニアをベースとする構造材料の湿式法による射出成形
US6009390A (en) 1997-09-11 1999-12-28 Lucent Technologies Inc. Technique for selective use of Gaussian kernels and mixture component weights of tied-mixture hidden Markov models for speech recognition
DE19753534A1 (de) 1997-12-03 1999-06-10 Bayer Ag Schnell kristallisierende, biologisch abbaubare Polyesteramide
CA2314896C (fr) 1997-12-22 2005-09-13 Euro-Celtique, S.A. Procede prevenant l'abus des doses orales d'opioides
DE19800689C1 (de) 1998-01-10 1999-07-15 Deloro Stellite Gmbh Formkörper aus einem verschleißfesten Werkstoff
DE19800698A1 (de) 1998-01-10 1999-07-15 Bayer Ag Biologisch abbaubare Polyesteramide mit blockartig aufgebauten Polyester- und Polyamid-Segmenten
US6251430B1 (en) 1998-02-04 2001-06-26 Guohua Zhang Water insoluble polymer based sustained release formulation
EP1045885A1 (fr) 1998-02-06 2000-10-25 Union Carbide Chemicals & Plastics Technology Corporation Compositions polymeres d'oxyde d'alkylene
JP3753254B2 (ja) 1998-03-05 2006-03-08 三井化学株式会社 ポリ乳酸樹脂組成物及びそれからなるフィルム
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6090411A (en) 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
US6110500A (en) 1998-03-25 2000-08-29 Temple University Coated tablet with long term parabolic and zero-order release kinetics
DK1067910T3 (da) 1998-04-03 2004-10-04 Egalet As Komposition med styret afgivelse
US5962488A (en) 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
DE19822979A1 (de) 1998-05-25 1999-12-02 Kalle Nalo Gmbh & Co Kg Folie mit Stärke oder Stärkederivaten und Polyesterurethanen sowie Verfahren zu ihrer Herstellung
US6333087B1 (en) 1998-08-27 2001-12-25 Chevron Chemical Company Llc Oxygen scavenging packaging
DE19841244A1 (de) 1998-09-09 2000-03-16 Knoll Ag Verfahren und Vorrichtung zum Herstellen von Tabletten
GT199900148A (es) 1998-09-10 2001-02-28 Desnaturalizantes para las sales aminas simpaticomimeticas.
CN1327384A (zh) 1998-10-20 2001-12-19 韩国科学技术研究院 作为血浆高密度脂蛋白浓度增高剂的生物类黄酮
US20010055613A1 (en) 1998-10-21 2001-12-27 Beth A. Burnside Oral pulsed dose drug delivery system
US20060240105A1 (en) 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
ES2141688B1 (es) 1998-11-06 2001-02-01 Vita Invest Sa Nuevos esteres derivados de compuestos fenil-ciclohexil sustituidos.
DE19855440A1 (de) 1998-12-01 2000-06-08 Basf Ag Verfahren zum Herstellen fester Darreichungsformen mittels Schmelzextrusion
DE19856147A1 (de) 1998-12-04 2000-06-08 Knoll Ag Teilbare feste Dosierungsformen und Verfahren zu ihrer Herstellung
EP1005863A1 (fr) 1998-12-04 2000-06-07 Synthelabo Formes galeniques a liberation controlee contenant un hypnotique a activite courte ou un sel de ce compose
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6238697B1 (en) 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
AU3469100A (en) 1999-01-05 2000-07-24 Copley Pharmaceutical Inc. Sustained release formulation with reduced moisture sensitivity
WO2000045830A1 (fr) 1999-02-04 2000-08-10 Nichimo Co., Ltd. Substances permettant d'eviter la survenue de l'arteriosclerose, substances immunostimulantes, vertebres nourris a l'aide ces substances et oeufs de ces vertebres
US6384020B1 (en) 1999-07-14 2002-05-07 Shire Laboratories, Inc. Rapid immediate release oral dosage form
MXPA02000725A (es) 1999-07-29 2003-07-14 Roxane Lab Inc Formulacion opioide de liberacion sostenida.
US20030118641A1 (en) 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
US6562375B1 (en) 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
HU229295B1 (en) 1999-08-04 2013-10-28 Astellas Pharma Inc Stable medicinal compositions for oral use
KR100345214B1 (ko) 1999-08-17 2002-07-25 이강춘 생체적합성 고분자가 수식된 펩타이드의 비점막 전달
US6198226B1 (en) * 1999-08-18 2001-03-06 Astronics Corporation Low-noise drive circuit for electroluminescent lamp, and electroluminescent lamp assembly comprising same
ATE279186T1 (de) 1999-08-31 2004-10-15 Gruenenthal Gmbh Retardierte darreichungsform enthaltend tramadolsaccharinat
DE19940944B4 (de) 1999-08-31 2006-10-12 Grünenthal GmbH Retardierte, orale, pharmazeutische Darreichungsformen
ES2160534B1 (es) 1999-12-30 2002-04-16 Vita Invest Sa Nuevos esteres derivados de (rr,ss)-2-hidroxibenzoato de 3-(2-dimetilaminometil-1-hidroxiciclohexil) fenilo.
US6680070B1 (en) 2000-01-18 2004-01-20 Albemarle Corporation Particulate blends and compacted products formed therefrom, and the preparation thereof
DE10015479A1 (de) 2000-03-29 2001-10-11 Basf Ag Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
US8012504B2 (en) 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6572887B2 (en) 2000-05-01 2003-06-03 National Starch And Chemical Investment Holding Corporation Polysaccharide material for direct compression
US6419954B1 (en) 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
AU2001274947B2 (en) * 2000-05-23 2006-08-17 Acorda Therapeutics, Inc. Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
JP4696210B2 (ja) * 2000-06-07 2011-06-08 トーアエイヨー株式会社 イソソルビド‐５‐モノニトレートを有効成分とする徐放性錠剤及びその製造方法
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6607748B1 (en) 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
DE10036400A1 (de) 2000-07-26 2002-06-06 Mitsubishi Polyester Film Gmbh Weiße, biaxial orientierte Polyesterfolie
WO2002026262A2 (fr) 2000-09-25 2002-04-04 Pro-Pharmaceuticals, Inc. Procedes et compositions permettant de reduire les effets secondaires lies aux traitements de chimiotherapie
EP1322188A1 (fr) 2000-09-27 2003-07-02 Danisco A/S Agent antimicrobien
AU2001294902A1 (en) 2000-09-28 2002-04-08 The Dow Chemical Company Polymer composite structures useful for controlled release systems
GB0026137D0 (en) 2000-10-25 2000-12-13 Euro Celtique Sa Transdermal dosage form
US6344215B1 (en) 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
MXPA03003895A (es) 2000-10-30 2003-07-28 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada.
AU2002226098A1 (en) 2000-10-30 2002-05-15 The Board Of Regents, The University Of Texas System Spherical particles produced by a hot-melt extrusion/spheronization process
DE10109763A1 (de) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
JP2002265592A (ja) 2001-03-07 2002-09-18 Sumitomo Seika Chem Co Ltd アルキレンオキシド重合体の製造方法
WO2002071860A1 (fr) 2001-03-13 2002-09-19 L.A. Dreyfus Co. Base de gomme et fabrication de base de gomme en utilisant des ingredients a base de gomme particulaire
JP3967554B2 (ja) 2001-03-15 2007-08-29 株式会社ポッカコーポレーション フラボノイド化合物及びその製造方法
US20020132395A1 (en) 2001-03-16 2002-09-19 International Business Machines Corporation Body contact in SOI devices by electrically weakening the oxide under the body
EP1241110A1 (fr) 2001-03-16 2002-09-18 Pfizer Products Inc. Unité de distribution pour médicaments sensibles à l'oxygène
AU2002248792B2 (en) 2001-04-18 2006-09-21 Nostrum Pharmaceuticals Inc. A novel coating for a sustained release pharmaceutical composition
US20020187192A1 (en) * 2001-04-30 2002-12-12 Yatindra Joshi Pharmaceutical composition which reduces or eliminates drug abuse potential
DE60211885T2 (de) 2001-05-01 2006-11-02 Union Carbide Chemicals & Plastics Technology Corp., Danbury Pharmazeutische zusammensetzung enthaltend polyalkylenoxide mit verringerten mengen an ameisensäure und ameisensäurederivaten
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
WO2002090316A1 (fr) 2001-05-08 2002-11-14 The Johns Hopkins University Procede d'inhibition de la synthese de la methamphetamine
CA2446550C (fr) 2001-05-11 2012-03-06 Endo Pharmaceuticals, Inc. Forme posologique d'opioides a liberation prolongee empechant la consommation abusive
EP1389092B1 (fr) 2001-05-11 2006-11-15 Endo Pharmaceuticals Inc. Forme de dosage d'opioides empechant la consommation abusive
US6623754B2 (en) 2001-05-21 2003-09-23 Noveon Ip Holdings Corp. Dosage form of N-acetyl cysteine
WO2002094172A2 (fr) 2001-05-22 2002-11-28 Euro-Celtique Forme posologique compartimentee
US20030064122A1 (en) 2001-05-23 2003-04-03 Endo Pharmaceuticals, Inc. Abuse resistant pharmaceutical composition containing capsaicin
WO2003002100A1 (fr) 2001-06-26 2003-01-09 Farrell John J Systeme d'administration de narcotique inviolable
AU2002320309B2 (en) 2001-07-06 2007-07-12 Endo Pharmaceuticals, Inc. Oxymorphone controlled release formulations
US7276250B2 (en) 2001-07-06 2007-10-02 Penwest Pharmaceuticals Company Sustained release formulations of oxymorphone
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
JP2003020517A (ja) 2001-07-10 2003-01-24 Calp Corp 複合繊維用樹脂組成物
US6883976B2 (en) * 2001-07-30 2005-04-26 Seikoh Giken Co., Ltd. Optical fiber ferrule assembly and optical module and optical connector using the same
KR20040025741A (ko) 2001-08-06 2004-03-25 유로-셀티크 소시에떼 아노뉨 오피오이드 남용을 방지하기 위한 조성물 및 방법
US7141250B2 (en) * 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US7144587B2 (en) * 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
KR20040060917A (ko) 2001-08-06 2004-07-06 유로-셀티크 소시에떼 아노뉨 오피오이드 남용을 방지하기 위한 조성물 및 방법
US20030049272A1 (en) 2001-08-30 2003-03-13 Yatindra Joshi Pharmaceutical composition which produces irritation
US6691698B2 (en) 2001-09-14 2004-02-17 Fmc Technologies Inc. Cooking oven having curved heat exchanger
US20030059467A1 (en) 2001-09-14 2003-03-27 Pawan Seth Pharmaceutical composition comprising doxasozin
US20030059397A1 (en) 2001-09-17 2003-03-27 Lyn Hughes Dosage forms
US20030092724A1 (en) 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
DK1429734T3 (da) 2001-09-21 2008-05-13 Egalet As Faste dispersioner af carvedilol til kontrolleret afgivelse
WO2003024430A1 (fr) 2001-09-21 2003-03-27 Egalet A/S Systeme a liberation de polymere de morphine
EP1429735A2 (fr) 2001-09-26 2004-06-23 Klaus-Jürgen Steffens Procede et dispositif de production de granules comprenant au moins un principe actif pharmaceutique
CA2459976A1 (fr) 2001-09-26 2003-04-03 Penwest Pharmaceuticals Company Formulations d'opioides presentant un potentiel reduit pour des utilisations abusives
CN1592610A (zh) 2001-09-28 2005-03-09 麦克内尔-Ppc股份有限公司 改良的释放剂型
US6837696B2 (en) 2001-09-28 2005-01-04 Mcneil-Ppc, Inc. Apparatus for manufacturing dosage forms
WO2003031546A1 (fr) 2001-10-09 2003-04-17 The Procter & Gamble Company Compositions aqueuses pour le traitement d'une surface
US6592901B2 (en) 2001-10-15 2003-07-15 Hercules Incorporated Highly compressible ethylcellulose for tableting
JP2003125706A (ja) 2001-10-23 2003-05-07 Lion Corp 口中清涼製剤
US20030104052A1 (en) 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030152622A1 (en) 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
CA2409552A1 (fr) 2001-10-25 2003-04-25 Depomed, Inc. Forme posologique orale pouvant etre retenue dans l'estomac dont la liberation est limitee a la partie inferieure du tube digestif
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
JP4551089B2 (ja) 2001-10-29 2010-09-22 マサチューセッツ インスティテュート オブ テクノロジー 三次元印刷により製造されたゼロ次放出プロフィール投薬形態のような徐放投薬形態を製造するためのシステム
US20040126428A1 (en) 2001-11-02 2004-07-01 Lyn Hughes Pharmaceutical formulation including a resinate and an aversive agent
JP2005508372A (ja) 2001-11-02 2005-03-31 エラン コーポレーシヨン ピーエルシー 薬剤組成物
EP1463515A4 (fr) 2001-12-06 2005-01-12 Scolr Pharma Inc Composition d'isoflavone a administration orale
FR2833838B1 (fr) 2001-12-21 2005-09-16 Ellipse Pharmaceuticals Procede de fabrication d'un comprime incluant un analgesique de type morphinique et comprime obtenu
AUPS044502A0 (en) 2002-02-11 2002-03-07 Commonwealth Scientific And Industrial Research Organisation Novel catalysts and processes for their preparation
US20040033253A1 (en) 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
US20030158265A1 (en) 2002-02-20 2003-08-21 Ramachandran Radhakrishnan Orally administrable pharmaceutical formulation comprising pseudoephedrine hydrochloride and process for preparing the same
US20030190343A1 (en) 2002-03-05 2003-10-09 Pfizer Inc. Palatable pharmaceutical compositions for companion animals
US6572889B1 (en) 2002-03-07 2003-06-03 Noveon Ip Holdings Corp. Controlled release solid dosage carbamazepine formulations
US6753009B2 (en) 2002-03-13 2004-06-22 Mcneil-Ppc, Inc. Soft tablet containing high molecular weight polyethylene oxide
ES2627298T3 (es) 2002-04-05 2017-07-27 Mundipharma Pharmaceuticals S.L. Preparación farmacéutica que contiene oxicodona y naloxona
DE10217232B4 (de) 2002-04-18 2004-08-19 Ticona Gmbh Verfahren zur Herstellung gefüllter Granulate aus Polyethylenen hohen bzw. ultrahohen Molekulargewichts
WO2003089506A1 (fr) 2002-04-22 2003-10-30 Purdue Research Foundation Hydrogels presentant des proprietes d'elasticite et de resistance mecanique ameliorees
CN1665482A (zh) 2002-04-29 2005-09-07 阿尔扎公司 羟可待酮控制输送给药的方法和剂型
US20050106249A1 (en) 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
EP1515674A4 (fr) 2002-05-13 2008-04-09 Endo Pharmaceuticals Inc Forme pharmaceutique solide opioide a l'epreuve des abus d'opioides
CN1671358A (zh) 2002-05-31 2005-09-21 阿尔扎公司 用于渗透传递可变剂量的羟考酮的剂型和组合物
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10250083A1 (de) 2002-06-17 2003-12-24 Gruenenthal Gmbh Gegen Missbrauch gesicherte Darreichungsform
US20070196481A1 (en) 2002-07-25 2007-08-23 Amidon Gregory E Sustained-release tablet composition
US20060099250A1 (en) 2002-08-21 2006-05-11 Wei Tian Use of an aqueous solution of citric acid and a water-soluble sugar like lactitol as granulation liquid in the manufacture of tablets
US7388068B2 (en) 2002-08-21 2008-06-17 Clariant Produkte (Deutschland) Gmbh Copolymers made of alkylene oxides and glycidyl ethers and use thereof as polymerizable emulsifiers
US20040077677A1 (en) 2002-09-17 2004-04-22 Wyeth Oral formulations
JP4195447B2 (ja) 2002-09-20 2008-12-10 エフ エム シー コーポレーション ミクロ結晶性セルロースを含有する化粧品用組成物
WO2004026308A1 (fr) 2002-09-21 2004-04-01 Shuyi Zhang Compose d'acetamidophenol et de tramadol a liberation prolongee
EP1551402A4 (fr) * 2002-09-23 2009-05-27 Verion Inc Compositions pharmaceutiques n'induisant pas l'abus
JP2004143071A (ja) 2002-10-23 2004-05-20 Hosokawa Funtai Gijutsu Kenkyusho:Kk 薬物含有複合粒子の製造方法および薬物含有複合粒子
US20050186139A1 (en) 2002-10-25 2005-08-25 Gruenenthal Gmbh Abuse-proofed dosage form
WO2004037222A2 (fr) 2002-10-25 2004-05-06 Labopharm Inc. Preparations de tramadol a liberation soutenue dotees d'une efficacite de 24 heures
DE10250084A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10250087A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20050191244A1 (en) 2002-10-25 2005-09-01 Gruenenthal Gmbh Abuse-resistant pharmaceutical dosage form
DE10250088A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20040091528A1 (en) 2002-11-12 2004-05-13 Yamanouchi Pharma Technologies, Inc. Soluble drug extended release system
US7018658B2 (en) 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
US20040121003A1 (en) 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
US7442387B2 (en) * 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
MXPA05009757A (es) 2003-03-13 2005-12-05 Controlled Chemicals Inc Conjugados de oxicodona con menor potencial de abuso y duracion de accion extendida.
ATE454886T1 (de) 2003-03-26 2010-01-15 Egalet As Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen
DE602004031096D1 (de) 2003-03-26 2011-03-03 Egalet As Morphin-system mit kontrollierter freisetzung
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
WO2004093819A2 (fr) 2003-04-21 2004-11-04 Euro-Celtique, S.A. Forme posologique inviolable contenant des particules co-extrudees d'agent repulsif contraire et procede de fabrication
ME00276B (fr) 2003-04-30 2011-05-10 Purdue Pharma Lp Forme posologique transdermique a fermeture inviolable
JP2004354981A (ja) 2003-05-06 2004-12-16 Fuji Photo Film Co Ltd 画像パターン記録方法
US8906413B2 (en) 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
CN1473562A (zh) 2003-06-27 2004-02-11 辉 刘 儿用口腔速溶、速崩冻干片及其制备方法
RU2339365C2 (ru) 2003-08-06 2008-11-27 Грюненталь Гмбх Защищенная от применения не по назначению лекарственная форма
JP4939217B2 (ja) 2003-08-06 2012-05-23 グリューネンタ−ル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 乱用防止剤形
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004020220A1 (de) 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
WO2005032555A2 (fr) 2003-09-25 2005-04-14 Euro-Celtique S.A. Combinaisons pharmaceutiques d'hydrocodone et de naltrexone
AU2004277980A1 (en) 2003-09-30 2005-04-14 Alza Corporation Osmotically driven active agent delivery device providing an ascending release profile
US20060172006A1 (en) 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
AU2004285547A1 (en) 2003-10-29 2005-05-12 Alza Corporation Once-a-day, oral, controlled-release, oxycodone dosage forms
BRPI0417348A (pt) 2003-12-04 2007-03-13 Pfizer Prod Inc processo de gelatinização por spray com utilização de uma extrusora para preparação de composições de droga cristalina multiparticulada contendo preferencialmente um poloxámero e um glicerìdeo
SI1691892T1 (sl) 2003-12-09 2007-08-31 Euro Celtique Sa Varnostna koekstrudirana dozirna oblika, ki vsebuje aktivno sredstvo in protisredstvo, in postopek njene izdelave
WO2005060942A1 (fr) 2003-12-19 2005-07-07 Aurobindo Pharma Ltd Composition pharmaceutique de metformine a liberation prolongee
DE10360792A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
WO2005065646A2 (fr) 2003-12-29 2005-07-21 Alza Corporation, Inc., Compositions medicamenteuses et formes pharmaceutiques
US20070196396A1 (en) 2004-02-11 2007-08-23 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0403100D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Particulates
GB0403098D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
KR100789227B1 (ko) 2004-02-23 2008-01-02 유로-셀띠끄 소시에떼 아노님 남용 방지 오피오이드 경피 전달 장치
US20050220877A1 (en) 2004-03-31 2005-10-06 Patel Ashish A Bilayer tablet comprising an antihistamine and a decongestant
EP1740156B8 (fr) 2004-04-22 2012-07-11 Grünenthal GmbH Procede de production d'une forme galenique solide protegee contre un usage detourne
WO2005105036A1 (fr) 2004-04-28 2005-11-10 Natco Pharma Limited Matrice muco-adhesive a liberation controlee contenant de la tolterodine, et procede d'elaboration
US20050271594A1 (en) 2004-06-04 2005-12-08 Groenewoud Pieter J Abuse resistent pharmaceutical composition
ATE368639T1 (de) 2004-06-28 2007-08-15 Gruenenthal Gmbh Kristalline formen von (-)-(1r,2r)-3-(3- dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochlorid
ITMI20041317A1 (it) 2004-06-30 2004-09-30 Ibsa Inst Biochimique Sa Formulazioni farmaceutiche per la somministrazione sicura di farmaci utilizzati nel trattamento della tossicodipendenza e procedimento per il loro ottenimento
EP1765298B1 (fr) 2004-07-01 2012-10-24 Gruenenthal Gmbh Procede de production d'une forme posologique solide anti-abus au moyen d'une extrudeuse a vis planetaires
PL1765303T5 (pl) 2004-07-01 2023-05-22 Grünenthal GmbH Tabletka doustna zabezpieczona przed nadużywaniem
BRPI0513300B1 (pt) 2004-07-01 2018-11-06 Gruenenthal Gmbh forma farmacêutica oral, protegida frente ao abuso, contendo (1r, 2r)-3-(3-dimetilamino-1-etil-2- metil-lpropil)-fenol
US7947259B2 (en) 2004-07-27 2011-05-24 Conopco, Inc. Hair care compositions
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
US20070077297A1 (en) 2004-09-30 2007-04-05 Scolr Pharma, Inc. Modified release ibuprofen dosage form
US20060068009A1 (en) 2004-09-30 2006-03-30 Scolr Pharma, Inc. Modified release ibuprofen dosage form
US7426948B2 (en) 2004-10-08 2008-09-23 Phibrowood, Llc Milled submicron organic biocides with narrow particle size distribution, and uses thereof
US20070231268A1 (en) 2004-11-24 2007-10-04 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060177380A1 (en) 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20080152595A1 (en) 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
DK1849470T4 (en) 2005-01-26 2024-04-02 Taiho Pharmaceutical Co Ltd Cancerlægemiddel, som indeholder alpha, alpha, alpha-trifluorthymidin og thymidin-phosphorylase-inhibitor
BRPI0606339A2 (pt) 2005-01-28 2009-06-16 Euro Celtique Sa formas farmacêuticas resistentes a álcool
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
FR2889810A1 (fr) 2005-05-24 2007-02-23 Flamel Technologies Sa Forme medicamenteuse orale, microparticulaire, anti-mesurage
AU2006212609A1 (en) 2005-02-10 2006-08-17 Lifecycle Pharma A/S A stable pharmaceutical composition comprising a fixed dose combination of fenofibrate and an HMG-CoA reductase inhibitor
US20060194759A1 (en) 2005-02-25 2006-08-31 Eidelson Stewart G Topical compositions and methods for treating pain and inflammation
EP1695700A1 (fr) 2005-02-28 2006-08-30 Euro-Celtique S.A. Forme posologique contenant de l'oxycodone et de la naloxone
SI2112153T1 (sl) 2005-03-04 2011-02-28 Euro Celtique Sa Postopek za zmanjšanje alfa, beta-nenasičenih ketonov v opioidnih sestavkih
US20060204575A1 (en) 2005-03-11 2006-09-14 Hengsheng Feng Amphetamine formulations
US7732427B2 (en) 2005-03-31 2010-06-08 University Of Delaware Multifunctional and biologically active matrices from multicomponent polymeric solutions
CN101227892B (zh) 2005-04-08 2013-06-05 舌交付有限公司 口腔给药系统
KR20130135403A (ko) 2005-05-10 2013-12-10 노파르티스 아게 압축성이 열등한 치료학적 화합물을 갖는 조성물을 제조하는 압출방법
CN101188999B (zh) 2005-06-03 2012-07-18 尹格莱特股份有限公司 用于递送分散在分散介质中的活性物质的药物传递系统
WO2007005716A2 (fr) 2005-06-30 2007-01-11 Cinergen, Llc Methodes de traitement et leurs compositions d'utilisation
US8221792B2 (en) 2005-07-07 2012-07-17 Farnam Companies, Inc. Sustained release pharmaceutical compositions for highly water soluble drugs
DE102005032806A1 (de) 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
US8858993B2 (en) 2005-07-25 2014-10-14 Metrics, Inc. Coated tablet with zero-order or near zero-order release kinetics
WO2007016563A2 (fr) 2005-08-01 2007-02-08 Alpharma Inc. Formulations pharmaceutiques resistantes a l'alcool
EP1909760A1 (fr) 2005-08-03 2008-04-16 Eastman Chemical Company Poudre de succinate de tocopheryl polyethylene glycol et procede de preparation de celle-ci
US20070048373A1 (en) 2005-08-30 2007-03-01 Cima Labs Inc. Dried milled granulate and methods
CA2625055C (fr) 2005-10-14 2013-12-24 The Kitasato Institute Nouveaux derives de dihydropseudoerythromycine
US20070092573A1 (en) 2005-10-24 2007-04-26 Laxminarayan Joshi Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US8329744B2 (en) 2005-11-02 2012-12-11 Relmada Therapeutics, Inc. Methods of preventing the serotonin syndrome and compositions for use thereof
US9125833B2 (en) 2005-11-02 2015-09-08 Relmada Therapeutics, Inc. Multimodal abuse resistant and extended release opioid formulations
FR2892937B1 (fr) 2005-11-10 2013-04-05 Flamel Tech Sa Forme pharmaceutique orale microparticulaire anti-mesusage
DE102005058569B4 (de) 2005-12-08 2010-07-15 Lts Lohmann Therapie-Systeme Ag Schaumwafer mit Polyvinylalkohol-Polyethylenglycol-Pfropfcopolymer
US20100172989A1 (en) 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
US20090317355A1 (en) 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
WO2007085024A2 (fr) 2006-01-21 2007-07-26 Abbott Gmbh & Co. Kg Forme dosifiée et méthode d'administration de drogues toxicomanogènes
EP1813276A1 (fr) 2006-01-27 2007-08-01 Euro-Celtique S.A. Formes de dosage inviolables
FR2897267A1 (fr) 2006-02-16 2007-08-17 Flamel Technologies Sa Formes pharmaceutiques multimicroparticulaires pour administration per os
ATE448231T1 (de) 2006-03-02 2009-11-15 Mallinckrodt Inc Verfahren zur herstellung von morphinan-6-on- produkten mit geringen konzentrationen von alpha-,beta-ungesättigten ketonverbindungen
EP2086515A2 (fr) 2006-03-02 2009-08-12 Vaunnex, Inc. Formulations bioadhésives posologiques orales a liberation controlee
JP5536446B2 (ja) 2006-03-24 2014-07-02 オクシリウム インターナショナル ホールディングス，インコーポレイティド アルカリ不安定ドラッグを含む安定化された組成物
WO2007112285A2 (fr) 2006-03-24 2007-10-04 Auxilium Pharmaceuticals, Inc. Procede de preparation d'un stratifie extrude a chaud
US20070224637A1 (en) 2006-03-24 2007-09-27 Mcauliffe Joseph C Oxidative protection of lipid layer biosensors
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US9023400B2 (en) 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
WO2007138466A2 (fr) 2006-06-01 2007-12-06 Wockhardt Ltd Compositions pharmaceutiques comprenant une combinaison de meloxicam et de tramadol
US20070292508A1 (en) 2006-06-05 2007-12-20 Balchem Corporation Orally disintegrating dosage forms
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
RU2445077C2 (ru) 2006-06-19 2012-03-20 АЛФАРМА, Инк. Фармацевтические композиции
CN101091721A (zh) 2006-06-22 2007-12-26 孙明 阿胶新剂型的制备方法
EP2043613A1 (fr) 2006-07-14 2009-04-08 Fmc Corporation Forme solide
JP4029109B1 (ja) 2006-07-18 2008-01-09 タマ生化学株式会社 ビタミンｅとプロリンの複合体粉末及びその製造方法
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US8187636B2 (en) 2006-09-25 2012-05-29 Atlantic Pharmaceuticals, Inc. Dosage forms for tamper prone therapeutic agents
AU2006349402A1 (en) 2006-10-10 2008-04-17 Penwest Pharmaceuticals Co. Robust sustained release formulations
US20080085304A1 (en) 2006-10-10 2008-04-10 Penwest Pharmaceuticals Co. Robust sustained release formulations
GB0624880D0 (en) 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
DE102006062120A1 (de) 2006-12-22 2008-06-26 Grünenthal GmbH Pharmazeutische Zusammensetzung zur Aknebehandlung
EP2063867A2 (fr) 2006-12-22 2009-06-03 Combinatorx, Incorporated Compositions pharmaceutiques pour le traitement de la maladie de parkinson et de troubles apparentés
EP2104493A2 (fr) 2007-01-16 2009-09-30 Egalet A/S Utilisation (i) d'un polyglycol et (ii) d'une substance médicamenteuse active dans la préparation d'une composition pharmaceutique destinée (i) à réduire le risque de libération massive induite par l'alcool et/ou (ii) à réduire le risque de toxicomanie médicamenteuse
WO2008094877A2 (fr) 2007-01-30 2008-08-07 Drugtech Corporation Compositions pour l'administration orale de produits pharmaceutiques
CN100579525C (zh) 2007-02-02 2010-01-13 东南大学 盐酸尼卡地平缓释制剂及其制备方法
CN101057849A (zh) 2007-02-27 2007-10-24 齐齐哈尔医学院 含有盐酸二甲双胍和格列吡嗪的缓释制剂及其制备方法
US10888521B2 (en) 2007-03-02 2021-01-12 Farnam Companies, Inc. Sustained release compositions using wax-like materials
EP1980245A1 (fr) 2007-04-11 2008-10-15 Cephalon France Composition pharmaceutique bicouche lyophilisée et ses procédés de fabrication et d'utilisation
US20080260836A1 (en) 2007-04-18 2008-10-23 Thomas James Boyd Films Comprising a Plurality of Polymers
ES2963291T3 (es) 2007-04-26 2024-03-26 Sublimity Therapeutics Ltd Fabricación de múltiples minicápsulas
WO2008142627A2 (fr) 2007-05-17 2008-11-27 Ranbaxy Laboratories Limited Formulation multicouches à libération modifiée comprenant de l'amoxicilline et du clavulanate
US8202542B1 (en) 2007-05-31 2012-06-19 Tris Pharma Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
CA2690956C (fr) 2007-07-01 2017-01-03 Joseph Peter Habboushe Comprime de combinaison avec une couche exterieure pouvant etre machee
BRPI0721940A2 (pt) 2007-07-20 2014-03-18 Abbott Gmbh & Co Kg Formulações de analgésicos opióides confinados e não-opióides
EP2200591A2 (fr) 2007-09-11 2010-06-30 Ranbaxy Laboratories Limited Formes galéniques à libération contrôlée à base de trimétazidine
ES2611794T3 (es) 2007-09-13 2017-05-10 Cima Labs Inc. Formulación de medicamentos resistentes al abuso
US20100303883A1 (en) 2007-10-17 2010-12-02 Axxia Pharmaceuticals, Llc Polymeric drug delivery systems and thermoplastic extrusion processes for producing such systems
CN102908339A (zh) 2007-11-23 2013-02-06 格吕伦塔尔有限公司 他喷他多组合物
EP2219622A1 (fr) 2007-12-06 2010-08-25 Durect Corporation Procédés utiles dans le traitement de la douleur, d'états rhumatismaux ou d'inflammations associées à un état chronique
EP2229151B1 (fr) 2007-12-12 2012-08-08 Basf Se Sels de principes actifs ayant des contre-ions polymères
WO2009076764A1 (fr) 2007-12-17 2009-06-25 Labopharm Inc. Formulation à libération contrôlée évitant les utilisations impropres
KR100970665B1 (ko) 2008-02-04 2010-07-15 삼일제약주식회사 알푸조신 또는 그의 염을 함유하는 서방성 정제
CA2717456A1 (fr) 2008-03-05 2009-09-11 Panacea Biotec Limited Compositions pharmaceutiques a liberation modifiee comprenant du mycophenolate et procedes pour celles-ci
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
TWI519322B (zh) 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 包含弱鹼性藥物及控制釋放劑型之組合物
TWI524904B (zh) 2008-05-09 2016-03-11 歌林達股份有限公司 製備醫藥用固體劑型，尤指錠劑之方法，及製備固體劑型，尤指錠劑之前驅物之方法
JP2010062141A (ja) * 2008-08-04 2010-03-18 Komatsu Ltd 極端紫外光源装置
CN102271661A (zh) 2008-08-20 2011-12-07 德克萨斯州立大学董事会 缓释多颗粒的热熔挤出
FR2936709B1 (fr) 2008-10-02 2012-05-11 Ethypharm Sa Comprimes alcoolo-resistants.
WO2010044842A1 (fr) 2008-10-16 2010-04-22 University Of Tennessee Research Foundation Formes pharmaceutiques orales inviolables contenant un agent embolisant
CA2743639A1 (fr) 2008-11-14 2010-05-20 Patheon Inc. Composition solide pour liberation controlee d'agents actifs ionisables avec une faible solubilite aqueuse a ph bas, et procedes d'utilisation associes
WO2010066034A1 (fr) 2008-12-12 2010-06-17 Paladin Labs Inc. Préparation de méthadone
ES2509497T3 (es) 2008-12-16 2014-10-17 Paladin Labs Inc. Formulación de liberación controlada para evitar un uso indebido
EP2389169A1 (fr) 2009-01-26 2011-11-30 Egalet A/S Formulations à libération contrôlée avec efficacité continue
EP2393487B1 (fr) 2009-02-06 2016-11-02 Egalet Ltd. Compositions pharmaceutiques résistant à une maltraitance
CN102355893A (zh) 2009-03-18 2012-02-15 赢创罗姆有限公司 采用含有中性乙烯基聚合物和赋形剂的包衣的具有耐乙醇影响的控释药物组合物
EP2246063A1 (fr) 2009-04-29 2010-11-03 Ipsen Pharma S.A.S. Formulations à libération prolongée contenant des analogues de GnRH
GB0909680D0 (en) 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
CA2766179A1 (fr) 2009-06-24 2010-12-29 Egalet Ltd. Formulations a liberation controlee
WO2011008298A2 (fr) 2009-07-16 2011-01-20 Nectid, Inc. Nouvelles formes pharmaceutiques de l’axomadol
CA2765971C (fr) 2009-07-22 2017-08-22 Gruenenthal Gmbh Forme galenique extrudee a chaud a liberation controlee
EP2456425B1 (fr) 2009-07-22 2015-10-21 Grünenthal GmbH Formule de dosage inviolable pour opioïdes sensibles à l'oxydation
EP2488029B1 (fr) 2009-09-30 2016-03-23 Acura Pharmaceuticals, Inc. Procédés et compositions de dissuasion d'abus
US9044758B2 (en) 2009-11-13 2015-06-02 Moriroku Chemicals Company, Ltd. Method for producing fine powder and the fine powder produced by the same
EP2506838A1 (fr) 2009-12-01 2012-10-10 Noven Pharmaceuticals, INC. Dispositif d'administration transdermique de testostérone
US9579285B2 (en) 2010-02-03 2017-02-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
GB201003731D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
MX339408B (es) 2010-03-09 2016-05-24 Alkermes Pharma Ireland Ltd Composiciones farmaceuticas entericas resistentes al alcohol.
WO2011123866A1 (fr) 2010-04-02 2011-10-06 Alltranz Inc. Formulations transdermiques empêchant les abus constituées d'agonistes et d'agonistes/antagonistes d'opiacés
AU2011236548A1 (en) 2010-04-07 2012-11-01 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
GB201006200D0 (en) 2010-04-14 2010-06-02 Ayanda As Composition
US10463633B2 (en) 2010-04-23 2019-11-05 Kempharm, Inc. Therapeutic formulation for reduced drug side effects
US20130059010A1 (en) 2010-05-14 2013-03-07 Ethypharm Alcohol-resistant oral pharmaceutical form
FR2960775A1 (fr) 2010-06-07 2011-12-09 Ethypharm Sa Microgranules resistants au detournement
EP2611426B1 (fr) 2010-09-02 2014-06-25 Grünenthal GmbH Forme pharmaceutique inviolable comportant un sel inorganique
US20120202838A1 (en) 2010-11-04 2012-08-09 Abbott Laboratories Drug formulations
US20120231083A1 (en) 2010-11-18 2012-09-13 The Board Of Trustees Of The University Of Illinois Sustained release cannabinoid medicaments
GB201020895D0 (en) 2010-12-09 2011-01-26 Euro Celtique Sa Dosage form
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
CN103476401A (zh) 2011-02-17 2013-12-25 Qrx制药有限公司 用于预防固体剂型滥用的技术
BR112013022495A2 (pt) 2011-03-04 2016-12-06 Gruenenthal Gmbh formulação farmacêutica aquosa de tapentadol para administração oral
ES2646363T3 (es) 2011-04-29 2017-12-13 Grünenthal GmbH Tapentadol para la prevención y el tratamiento de la depresión y la ansiedad
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US20120328697A1 (en) 2011-06-01 2012-12-27 Fmc Corporation Controlled Release Solid Dose Forms
EP2726065A4 (fr) 2011-06-30 2014-11-26 Neos Therapeutics Lp Formes médicamenteuses résistant à l'abus
CN103857386A (zh) 2011-07-29 2014-06-11 格吕伦塔尔有限公司 提供药物立即释放的抗破碎片剂
IN2014CN00827A (fr) 2011-08-16 2015-04-03 Merck Sharp & Dohme
FR2979242A1 (fr) 2011-08-29 2013-03-01 Sanofi Sa Comprime contre l'usage abusif, a base de paracetamol et d'oxycodone
AU2012320496C1 (en) 2011-10-06 2017-09-28 Grünenthal GmbH Tamper-resistant oral pharmaceutical dosage form comprising opioid agonist and opioid antagonist
BR112014011504A2 (pt) 2011-11-17 2017-05-09 Gruenenthal Gmbh forma de dosagem farmacêutica oral inviolável compreendendo ingrediente farmacologicamente ativo, antagonista opioide e/ou agente aversivo, óxido de polialquileno e polímero aniônico
CN107854434A (zh) 2011-12-09 2018-03-30 普渡制药公司 包含聚(ε‑己内酯)和聚氧乙烯的药物剂型
JP2013155124A (ja) 2012-01-30 2013-08-15 Moriroku Chemicals Co Ltd 医薬品の原末及びその製造方法
US20130225625A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant pharmaceutical dosage form comprising nonionic surfactant
EP2819656A1 (fr) 2012-02-28 2015-01-07 Grünenthal GmbH Forme pharmaceutique inviolable comprenant un composé pharmacologiquement actif et un polymère anionique
JP6199321B2 (ja) 2012-03-02 2017-09-20 ローズ ファーマシューティカルズ エル．ピー． 不正使用抵抗性の即時放出製剤
PT2838512T (pt) 2012-04-18 2018-11-09 Gruenenthal Gmbh Forma farmacêutica resistente à adulteração e resistente à libertação inesperada de alta quantidade (dose-dumping)
MX2014011815A (es) 2012-04-18 2014-12-05 Mallinckrodt Llc Composiciones farmaceuticas de liberacion inmediata con propiedades disuasivas de abuso.
EA029171B1 (ru) 2012-05-11 2018-02-28 Грюненталь Гмбх Термоформованная устойчивая к разрушению фармацевтическая лекарственная форма, содержащая цинк, и способ ее получения
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CA2880163A1 (fr) 2012-08-01 2014-02-06 Acura Pharmaceuticals, Inc. Stabilisation de systemes de synthese de la methamphetamine en enceinte unique
RU2015110824A (ru) 2012-08-27 2016-10-20 Эвоник Индустрис Аг Фармацевтическая или нутрицевтическая композиция с замедленным высвобождением и стойкостью к воздействию этанола
HUE031818T2 (en) 2012-08-27 2017-08-28 Evonik Roehm Gmbh A stomach-resistant medical or nutritional preparation that is resistant to ethanol
JP5775223B2 (ja) 2012-09-05 2015-09-09 テイカ製薬株式会社 口腔内速崩壊性錠剤用造粒物
CA2888278A1 (fr) 2012-10-15 2014-04-24 Isa Odidi Formulations de medicament pour administration par voie orale
US9517208B2 (en) 2013-03-15 2016-12-13 Purdue Pharma L.P. Abuse-deterrent dosage forms
US10420729B2 (en) 2013-03-15 2019-09-24 R.P. Scherer Technologies, Llc Abuse resistant capsule
US20140275143A1 (en) 2013-03-15 2014-09-18 Mallinckrodt Llc Compositions Comprising An Opioid And An Additional Active Pharmaceutical Ingredient For Rapid Onset And Extended Duration Of Analgesia That May Be Administered Without Regard To Food
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
AU2014273226B2 (en) 2013-05-29 2019-06-27 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
CA2817728A1 (fr) 2013-05-31 2014-11-30 Pharmascience Inc. Formulation a liberation immediate de prevention des abus
EP3019157A1 (fr) 2013-07-12 2016-05-18 Grünenthal GmbH Forme posologique inviolable contenant un polymère d'éthylène-acétate de vinyle
JP6539274B2 (ja) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 押出成形された即放性乱用抑止性丸剤
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
WO2015048597A1 (fr) 2013-09-30 2015-04-02 Daya Drug Discoveries, Inc. Prévention de la fabrication illicite de méthamphétamine à partir de pseudoéphédrine à l'aide d'arômes alimentaires
WO2015065547A1 (fr) 2013-10-31 2015-05-07 Cima Labs Inc. Formes pharmaceutiques en granulés anti-abus à libération immédiate
WO2015103379A1 (fr) 2013-12-31 2015-07-09 Kashiv Pharma, Llc Formulations médicamenteuses anti-abus
US10632113B2 (en) 2014-02-05 2020-04-28 Kashiv Biosciences, Llc Abuse-resistant drug formulations with built-in overdose protection
US20160089439A1 (en) 2014-09-28 2016-03-31 Satara Pharmaceuticals, LLC Prevention of Illicit Manufacutre of Methamphetamine from Pseudoephedrine Using Food Flavor Excipients
US20170112766A1 (en) 2015-04-24 2017-04-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
US20160310429A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
US20170296476A1 (en) 2016-04-15 2017-10-19 Grünenthal GmbH Modified release abuse deterrent dosage forms

Patent Citations (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652589A (en) * 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
US4070497A (en) * 1971-03-09 1978-01-24 Ppg Industries, Inc. Process of applying and curing a plurality of coatings
US3865108A (en) * 1971-05-17 1975-02-11 Ortho Pharma Corp Expandable drug delivery device
US4014965A (en) * 1972-11-24 1977-03-29 The Dow Chemical Company Process for scrapless forming of plastic articles
US4002173A (en) * 1974-07-23 1977-01-11 International Paper Company Diester crosslinked polyglucan hydrogels and reticulated sponges thereof
US4070494A (en) * 1975-07-09 1978-01-24 Bayer Aktiengesellschaft Enteral pharmaceutical compositions
US4262017A (en) * 1978-05-22 1981-04-14 Basf Aktiengesellschaft Preparation of a vitamin E dry powder
US4200704A (en) * 1978-09-28 1980-04-29 Union Carbide Corporation Controlled degradation of poly(ethylene oxide)
US4427778A (en) * 1982-06-29 1984-01-24 Biochem Technology, Inc. Enzymatic preparation of particulate cellulose for tablet making
US4427681A (en) * 1982-09-16 1984-01-24 Richardson-Vicks, Inc. Thixotropic compositions easily convertible to pourable liquids
US5082668A (en) * 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US4992279A (en) * 1985-07-03 1991-02-12 Kraft General Foods, Inc. Sweetness inhibitor
US5198226A (en) * 1986-01-30 1993-03-30 Syntex (U.S.A.) Inc. Long acting nicardipine hydrochloride formulation
US4892889A (en) * 1986-11-18 1990-01-09 Basf Corporation Process for making a spray-dried, directly-compressible vitamin powder comprising unhydrolyzed gelatin
US4992278A (en) * 1987-01-14 1991-02-12 Ciba-Geigy Corporation Therapeutic system for sparingly soluble active ingredients
US5387420A (en) * 1988-08-26 1995-02-07 May & Baker Ltd. Morphine-containing efferverscent composition
US5190760A (en) * 1989-07-08 1993-03-02 Coopers Animal Health Limited Solid pharmaceutical composition
US5593694A (en) * 1991-10-04 1997-01-14 Yoshitomi Pharmaceutical Industries, Ltd. Sustained release tablet
US5508042A (en) * 1991-11-27 1996-04-16 Euro-Celtigue, S.A. Controlled release oxycodone compositions
US5378462A (en) * 1992-08-19 1995-01-03 Kali-Chemie Pharma Gmbh Pancreatin micropellets prepared with polyethylene glycol 4000, paraffin and a lower alcohol by extrusion and rounding
US5620697A (en) * 1992-12-31 1997-04-15 Orion-Yhtyma Oy Method for preparing matrix-type pharmaceutical compositions through ultrasonic means to accomplish melting
US5591452A (en) * 1993-05-10 1997-01-07 Euro-Celtique, S.A. Controlled release formulation
US5601842A (en) * 1993-09-03 1997-02-11 Gruenenthal Gmbh Sustained release drug formulation containing a tramadol salt
USRE39593E1 (en) * 1994-07-23 2007-04-24 Gruenenthal Gmbh 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects
US5707636A (en) * 1994-08-03 1998-01-13 Saitec S.R.L. Apparatus and method for preparing solid forms with controlled release of the active ingredient
US20040081694A1 (en) * 1994-11-04 2004-04-29 Euro-Celtique, S.A. Melt-extruded orally administrable opioid formulations
US6009690A (en) * 1994-12-23 2000-01-04 Basf Aktiengesellschaft Process and apparatus for the production of divisible tablets
US5741519A (en) * 1995-03-21 1998-04-21 Basf Aktiengesellschaft The production of active substance compositions in the form of a solid solution of the active substance in a polymer matrix, and active substance compositions produced by this process
US6348469B1 (en) * 1995-04-14 2002-02-19 Pharma Pass Llc Solid compositions containing glipizide and polyethylene oxide
US6337319B1 (en) * 1995-08-18 2002-01-08 Wuyi Wang μ-Selective opioid peptides
US6355656B1 (en) * 1995-12-04 2002-03-12 Celgene Corporation Phenidate drug formulations having diminished abuse potential
US5866164A (en) * 1996-03-12 1999-02-02 Alza Corporation Composition and dosage form comprising opioid antagonist
US6183781B1 (en) * 1996-05-14 2001-02-06 Alkermes Controlled Therapeutics, Inc. Method for fabricating polymer-based controlled-release devices
US6051253A (en) * 1996-07-23 2000-04-18 Basf Aktiengesellschaft Production of solid drug forms
US7176251B1 (en) * 1996-11-05 2007-02-13 Novamont S.P.A. Biodegradable polymeric compositions comprising starch and a thermoplastic polymer
US6547997B1 (en) * 1997-11-28 2003-04-15 Abbot Laboratories Method for producing solvent-free noncrystalline biologically active substances
US6344535B1 (en) * 1997-12-03 2002-02-05 Bayer Aktiengesellschaft Polyether ester amides
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US6547977B1 (en) * 1998-04-02 2003-04-15 Applied Materials Inc. Method for etching low k dielectrics
US20030017532A1 (en) * 1998-09-22 2003-01-23 Sanjoy Biswas ndp
US20030077297A1 (en) * 1999-02-26 2003-04-24 Feng-Jing Chen Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6375963B1 (en) * 1999-06-16 2002-04-23 Michael A. Repka Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof
US6723343B2 (en) * 1999-08-31 2004-04-20 Gruenenthal Gmbh Pharmaceutical tramadol salts
US20030015814A1 (en) * 1999-12-15 2003-01-23 Harald Krull Device and method for producing solid shape containing an active ingredient
US20110097404A1 (en) * 2000-02-08 2011-04-28 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US20020015730A1 (en) * 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
US20020012701A1 (en) * 2000-06-19 2002-01-31 Karl Kolter Process for producing solid oral dosage forms with sustained release of active ingredient
US20030008409A1 (en) * 2001-07-03 2003-01-09 Spearman Steven R. Method and apparatus for determining sunlight exposure
US20030069263A1 (en) * 2001-07-18 2003-04-10 Breder Christopher D. Pharmaceutical combinations of oxycodone and naloxone
US20070020188A1 (en) * 2001-08-06 2007-01-25 Purdue Pharma L.P. Pharmaceutical formulation containing irritant
US20050089475A1 (en) * 2001-08-06 2005-04-28 Thomas Gruber Pharmaceutical formulation containing dye
US20030068370A1 (en) * 2001-08-06 2003-04-10 Richard Sackler Pharmaceutical formulation containing irritant
US7157103B2 (en) * 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
US20090081287A1 (en) * 2001-08-06 2009-03-26 Purdue Pharma L.P. Pharmaceutical Composition Containing Gelling Agent
US20030068375A1 (en) * 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030068392A1 (en) * 2001-08-06 2003-04-10 Richard Sackler Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US20030068371A1 (en) * 2001-08-06 2003-04-10 Benjamin Oshlack Pharmaceutical formulation containing opioid agonist,opioid antagonist and gelling agent
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030031546A1 (en) * 2001-08-08 2003-02-13 Toshiyuki Araki Lift apparatus
US20030068276A1 (en) * 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
US20050058706A1 (en) * 2001-10-24 2005-03-17 Grunenthal Gmbh Delayed release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol
US20090017121A1 (en) * 2001-10-25 2009-01-15 Bret Berner Gastric retained gabapentin dosage form
US20040052731A1 (en) * 2002-07-05 2004-03-18 Collegium Pharmaceuticals, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US20040011806A1 (en) * 2002-07-17 2004-01-22 Luciano Packaging Technologies, Inc. Tablet filler device with star wheel
US20040052844A1 (en) * 2002-09-16 2004-03-18 Fang-Hsiung Hsiao Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
US20060004034A1 (en) * 2002-11-11 2006-01-05 Gruenenthal Gmbh Spirocyclic cyclohexane compounds
US20050015730A1 (en) * 2003-07-14 2005-01-20 Srimanth Gunturi Systems, methods and computer program products for identifying tab order sequence of graphically represented elements
US20120034171A1 (en) * 2003-08-06 2012-02-09 Gruenenthal Gmbh Abuse-proofed dosage form
US8114383B2 (en) * 2003-08-06 2012-02-14 Gruenenthal Gmbh Abuse-proofed dosage form
US20050031546A1 (en) * 2003-08-06 2005-02-10 Johannes Bartholomaus Abuse-proffed dosage form
US20050063214A1 (en) * 2003-09-22 2005-03-24 Daisaburo Takashima Semiconductor integrated circuit device
US20060009478A1 (en) * 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain
US7201920B2 (en) * 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US8101630B2 (en) * 2003-11-26 2012-01-24 Acura Pharmaceuticals, Inc. Extended release opioid abuse deterrent compositions and methods of making same
US20070003616A1 (en) * 2003-12-24 2007-01-04 Elisabeth Arkenau-Maric Process for the production of an abuse-proofed dosage form
US20090005408A1 (en) * 2003-12-24 2009-01-01 Grunenthal Gmbh Process for the production of an abuse-proofed dosage form
US7683072B2 (en) * 2004-03-30 2010-03-23 Purdue Pharma L.P. Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
US7674800B2 (en) * 2004-03-30 2010-03-09 Purdue Pharma L.P. Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
US7674799B2 (en) * 2004-03-30 2010-03-09 Purdue Pharma L.P. Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
US20070065365A1 (en) * 2004-04-21 2007-03-22 Gruenenthal Gmbh Abuse-resistant transdermal system
US20060017916A1 (en) * 2004-06-09 2006-01-26 Clarke Allan J Apparatus for producing a pharmaceutical product
US20060002859A1 (en) * 2004-07-01 2006-01-05 Elisabeth Arkenau Process for production of an abuse-proofed solid dosage form
US20060002860A1 (en) * 2004-07-01 2006-01-05 Johannes Bartholomaus Abuse-proofed oral dosage form
US20060039864A1 (en) * 2004-07-01 2006-02-23 Johannes Bartholomaus Abuse-proofed oral dosage form
US20100092553A1 (en) * 2005-11-10 2010-04-15 Flamel Technologies anti-misuse microparticulate oral pharmaceutical form
US20100015223A1 (en) * 2006-03-01 2010-01-21 Ethypharm Sa Crush-Resistant Tablets Intended to Prevent Accidental Misuse and Unlawful Diversion
US20090011016A1 (en) * 2006-03-01 2009-01-08 Ethypharm Sa Crush-Resistant Oxycodone Tablets Intended For Preventing Accidental Misuse And Unlawful Diversion
US20080069871A1 (en) * 2006-07-21 2008-03-20 Vaughn Jason M Hydrophobic abuse deterrent delivery system
US20090081290A1 (en) * 2006-08-25 2009-03-26 Purdue Pharma L.P. Tamper resistant dosage forms
US20080081290A1 (en) * 2006-09-25 2008-04-03 Fujifilm Corporation Resist composition, resin for use in the resist composition, compound for use in the synthesis of the resin, and pattern-forming method using the resist composition
US20090004267A1 (en) * 2007-03-07 2009-01-01 Gruenenthal Gmbh Dosage Form with Impeded Abuse
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
US8383152B2 (en) * 2008-01-25 2013-02-26 Gruenenthal Gmbh Pharmaceutical dosage form
US20110020454A1 (en) * 2008-03-13 2011-01-27 Rosa Lamarca Casado Novel dosage and formulation
US20110092515A1 (en) * 2008-07-03 2011-04-21 Zhihui Qiu Melt granulation process
US20100104638A1 (en) * 2008-10-27 2010-04-29 Wei-Guo Dai Extended release oral acetaminophen/tramadol dosage form
US20120059065A1 (en) * 2010-09-02 2012-03-08 Grünenthal GmbH Tamper Resistant Dosage Form Comprising An Anionic Polymer
US20120065220A1 (en) * 2010-09-02 2012-03-15 Grunenthal Gmbh Tamper Resistant Dosage Form Comprising An Anionic Polymer
US20130028970A1 (en) * 2011-07-29 2013-01-31 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Pinto, J.F., et al."Evaluation of the Potential Use of Poly(ethylene oxide) as Tablet- and Extrudate-Forming Material", 2004, AAPS PharmSci, pp. 1-10 *

Cited By (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9861583B2 (en) 2001-08-06 2018-01-09 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9044435B2 (en) 2001-08-06 2015-06-02 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9968559B2 (en) 2001-08-06 2018-05-15 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US10130586B2 (en) 2001-08-06 2018-11-20 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US11135171B2 (en) 2001-08-06 2021-10-05 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US10537526B2 (en) 2001-08-06 2020-01-21 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9387173B2 (en) 2001-08-06 2016-07-12 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9387174B2 (en) 2001-08-06 2016-07-12 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9034376B2 (en) 2001-08-06 2015-05-19 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9517207B2 (en) 2001-08-06 2016-12-13 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9861582B2 (en) 2001-08-06 2018-01-09 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9693961B2 (en) 2001-08-06 2017-07-04 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9308170B2 (en) 2001-08-06 2016-04-12 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9308171B2 (en) 2001-08-06 2016-04-12 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US10064824B2 (en) 2001-08-06 2018-09-04 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9867784B2 (en) 2001-08-06 2018-01-16 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9872836B2 (en) 2001-08-06 2018-01-23 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US10500160B2 (en) 2001-08-06 2019-12-10 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US8337888B2 (en) 2001-08-06 2012-12-25 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US10064825B2 (en) 2001-08-06 2018-09-04 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US8389007B2 (en) 2001-08-06 2013-03-05 Purdue Pharma L.P. Pharmaceutical composition containing gelling agent
US9867783B2 (en) 2001-08-06 2018-01-16 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US8529948B1 (en) 2001-08-06 2013-09-10 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US8609683B2 (en) 2001-08-06 2013-12-17 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US10071057B2 (en) 2001-08-06 2018-09-11 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9060976B2 (en) 2001-08-06 2015-06-23 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9877924B2 (en) 2001-08-06 2018-01-30 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US10076497B2 (en) 2001-08-06 2018-09-18 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US8871265B2 (en) 2001-08-06 2014-10-28 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US8999961B2 (en) 2001-08-06 2015-04-07 Purdue Pharma, L.P. Pharmaceutical formulation containing gelling agent
US9757341B2 (en) 2001-08-06 2017-09-12 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US10206881B2 (en) 2001-08-06 2019-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9040084B2 (en) 2001-08-06 2015-05-26 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US9675610B2 (en) 2002-06-17 2017-06-13 Grünenthal GmbH Abuse-proofed dosage form
US10369109B2 (en) 2002-06-17 2019-08-06 Grünenthal GmbH Abuse-proofed dosage form
US10525053B2 (en) 2002-07-05 2020-01-07 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US10130591B2 (en) 2003-08-06 2018-11-20 Grünenthal GmbH Abuse-proofed dosage form
US8309060B2 (en) 2003-08-06 2012-11-13 Grunenthal Gmbh Abuse-proofed dosage form
US20050031546A1 (en) * 2003-08-06 2005-02-10 Johannes Bartholomaus Abuse-proffed dosage form
US8420056B2 (en) 2003-08-06 2013-04-16 Grunenthal Gmbh Abuse-proofed dosage form
US8192722B2 (en) 2003-08-06 2012-06-05 Grunenthal Gmbh Abuse-proof dosage form
US8114383B2 (en) 2003-08-06 2012-02-14 Gruenenthal Gmbh Abuse-proofed dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US10058548B2 (en) 2003-08-06 2018-08-28 Grünenthal GmbH Abuse-proofed dosage form
US9629807B2 (en) 2003-08-06 2017-04-25 Grünenthal GmbH Abuse-proofed dosage form
US11224576B2 (en) 2003-12-24 2022-01-18 Grünenthal GmbH Process for the production of an abuse-proofed dosage form
US10525052B2 (en) 2004-06-12 2020-01-07 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
US8323889B2 (en) 2004-07-01 2012-12-04 Gruenenthal Gmbh Process for the production of an abuse-proofed solid dosage form
US8114384B2 (en) 2004-07-01 2012-02-14 Gruenenthal Gmbh Process for the production of an abuse-proofed solid dosage form
US11844865B2 (en) 2004-07-01 2023-12-19 Grünenthal GmbH Abuse-proofed oral dosage form
US10675278B2 (en) 2005-02-04 2020-06-09 Grünenthal GmbH Crush resistant delayed-release dosage forms
US10729658B2 (en) 2005-02-04 2020-08-04 Grünenthal GmbH Process for the production of an abuse-proofed dosage form
US20100210732A1 (en) * 2005-11-02 2010-08-19 Najib Babul Methods of Preventing the Serotonin Syndrome and Compositions for Use Therefor
US20100249045A1 (en) * 2005-11-02 2010-09-30 Theraquest Biosciences, Inc. Multimodal Abuse Resistant and Extended Release Opioid Formulations
US8329744B2 (en) 2005-11-02 2012-12-11 Relmada Therapeutics, Inc. Methods of preventing the serotonin syndrome and compositions for use thereof
US20080280975A1 (en) * 2005-11-02 2008-11-13 Theraquest Biosciences, Inc. Methods of preventing the serotonin syndrome and compositions for use thereof
US9125833B2 (en) 2005-11-02 2015-09-08 Relmada Therapeutics, Inc. Multimodal abuse resistant and extended release opioid formulations
US20090082466A1 (en) * 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
US20080075768A1 (en) * 2006-07-21 2008-03-27 Vaughn Jason M Hydrophobic opioid abuse deterrent delivery system using opioid antagonists
US20080075770A1 (en) * 2006-07-21 2008-03-27 Vaughn Jason M Hydrophilic abuse deterrent delivery system
US20080020032A1 (en) * 2006-07-21 2008-01-24 Michael Crowley Hydrophobic abuse deterrent delivery system for hydromorphone
US20080075771A1 (en) * 2006-07-21 2008-03-27 Vaughn Jason M Hydrophilic opioid abuse deterrent delivery system using opioid antagonists
US12280152B2 (en) 2006-08-25 2025-04-22 Purdue Pharma L.P. Tamper resistant dosage forms
US11904055B2 (en) 2006-08-25 2024-02-20 Purdue Pharma L.P. Tamper resistant dosage forms
US11298322B2 (en) 2006-08-25 2022-04-12 Purdue Pharma L.P. Tamper resistant dosage forms
US11304909B2 (en) 2006-08-25 2022-04-19 Purdue Pharma L.P. Tamper resistant dosage forms
US9545380B2 (en) 2006-08-25 2017-01-17 Purdue Pharma L.P. Tamper resistant dosage forms
US9492390B2 (en) 2006-08-25 2016-11-15 Purdue Pharma L.P. Tamper resistant dosage forms
US9492392B2 (en) 2006-08-25 2016-11-15 Purdue Pharma L.P. Tamper resistant dosage forms
US9492393B2 (en) 2006-08-25 2016-11-15 Purdue Pharma L.P. Tamper resistant dosage forms
US9492391B2 (en) 2006-08-25 2016-11-15 Purdue Pharma L.P. Tamper resistant dosage forms
US12396955B2 (en) 2006-08-25 2025-08-26 Purdue Pharma L.P. Tamper resistant dosage forms
US9492389B2 (en) 2006-08-25 2016-11-15 Purdue Pharma L.P. Tamper resistant dosage forms
US9486412B2 (en) 2006-08-25 2016-11-08 Purdue Pharma L.P. Tamper resistant dosage forms
US9763886B2 (en) 2006-08-25 2017-09-19 Purdue Pharma L.P. Tamper resistant dosage forms
US9763933B2 (en) 2006-08-25 2017-09-19 Purdue Pharma L.P. Tamper resistant dosage forms
US9770417B2 (en) 2006-08-25 2017-09-26 Purdue Pharma L.P. Tamper resistant dosage forms
US9770416B2 (en) 2006-08-25 2017-09-26 Purdue Pharma L.P. Tamper resistant dosage forms
US9775812B2 (en) 2006-08-25 2017-10-03 Purdue Pharma L.P. Tamper resistant dosage forms
US9775811B2 (en) 2006-08-25 2017-10-03 Purdue Pharma L.P. Tamper resistant dosage forms
US9775808B2 (en) 2006-08-25 2017-10-03 Purdue Pharma L.P. Tamper resistant dosage forms
US9775810B2 (en) 2006-08-25 2017-10-03 Purdue Pharma L.P. Tamper resistant dosage forms
US9775809B2 (en) 2006-08-25 2017-10-03 Purdue Pharma L.P. Tamper resistant dosage forms
US9486413B2 (en) 2006-08-25 2016-11-08 Purdue Pharma L.P. Tamper resistant dosage forms
US11304908B2 (en) 2006-08-25 2022-04-19 Purdue Pharma L.P. Tamper resistant dosage forms
US11826472B2 (en) 2006-08-25 2023-11-28 Purdue Pharma L.P. Tamper resistant dosage forms
US10076499B2 (en) 2006-08-25 2018-09-18 Purdue Pharma L.P. Tamper resistant dosage forms
US12246094B2 (en) 2006-08-25 2025-03-11 Purdue Pharma L.P. Tamper resistant dosage forms
US11938225B2 (en) 2006-08-25 2024-03-26 Purdue Pharm L.P. Tamper resistant dosage forms
US10076498B2 (en) 2006-08-25 2018-09-18 Purdue Pharma L.P. Tamper resistant dosage forms
US11964056B1 (en) 2006-08-25 2024-04-23 Purdue Pharma L.P Tamper resistant dosage forms
EP2692341A1 (fr) 2006-09-15 2014-02-05 Cima Labs Inc. Préparation médicamenteuse empêchant l'utilisation abusive
WO2008033523A1 (fr) 2006-09-15 2008-03-20 Cima Labs Inc. Préparation médicamenteuse empêchant l'utilisation abusive
US8722086B2 (en) 2007-03-07 2014-05-13 Gruenenthal Gmbh Dosage form with impeded abuse
US9642809B2 (en) 2007-06-04 2017-05-09 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
US8383152B2 (en) 2008-01-25 2013-02-26 Gruenenthal Gmbh Pharmaceutical dosage form
US9750701B2 (en) 2008-01-25 2017-09-05 Grünenthal GmbH Pharmaceutical dosage form
US9161917B2 (en) 2008-05-09 2015-10-20 Grünenthal GmbH Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet
US9005660B2 (en) 2009-02-06 2015-04-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
US9358295B2 (en) 2009-02-06 2016-06-07 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
US9023394B2 (en) 2009-06-24 2015-05-05 Egalet Ltd. Formulations and methods for the controlled release of active drug substances
US9925146B2 (en) 2009-07-22 2018-03-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
US10080721B2 (en) 2009-07-22 2018-09-25 Gruenenthal Gmbh Hot-melt extruded pharmaceutical dosage form
US10493033B2 (en) 2009-07-22 2019-12-03 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US9579285B2 (en) 2010-02-03 2017-02-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
US10300141B2 (en) 2010-09-02 2019-05-28 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
US9636303B2 (en) 2010-09-02 2017-05-02 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
US9572779B2 (en) 2010-12-22 2017-02-21 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US10966932B2 (en) 2010-12-22 2021-04-06 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US9861584B2 (en) 2010-12-22 2018-01-09 Purdue Pharma L.P. Tamper resistant controlled release dosage forms
US9744136B2 (en) 2010-12-22 2017-08-29 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US11911512B2 (en) 2010-12-22 2024-02-27 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US9393206B2 (en) 2010-12-22 2016-07-19 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US11590082B2 (en) 2010-12-22 2023-02-28 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US8808740B2 (en) 2010-12-22 2014-08-19 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US9872837B2 (en) 2010-12-22 2018-01-23 Purdue Pharma L.P. Tamper resistant controlled release dosage forms
US9750703B2 (en) 2010-12-22 2017-09-05 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
WO2012085657A2 (fr) 2010-12-23 2012-06-28 Purdue Pharma L.P. Formes pharmaceutiques solides à usage oral résistant à la contrefaçon
US9233073B2 (en) 2010-12-23 2016-01-12 Purdue Pharma L.P. Tamper resistant solid oral dosage forms
US9707180B2 (en) 2010-12-23 2017-07-18 Purdue Pharma L.P. Methods of preparing tamper resistant solid oral dosage forms
US9895317B2 (en) 2010-12-23 2018-02-20 Purdue Pharma L.P. Tamper resistant solid oral dosage forms
US20140070453A1 (en) * 2011-05-03 2014-03-13 Shl Group Ab Mold Assembly and Method for Manufacturing a Syringe Container
US10864164B2 (en) 2011-07-29 2020-12-15 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
US10201502B2 (en) 2011-07-29 2019-02-12 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
US10695297B2 (en) 2011-07-29 2020-06-30 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
US9655853B2 (en) 2012-02-28 2017-05-23 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
US10335373B2 (en) 2012-04-18 2019-07-02 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US10478504B2 (en) 2013-02-05 2019-11-19 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US11576974B2 (en) 2013-02-05 2023-02-14 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US10792364B2 (en) 2013-02-05 2020-10-06 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9149533B2 (en) 2013-02-05 2015-10-06 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9655971B2 (en) 2013-02-05 2017-05-23 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9662399B2 (en) 2013-02-05 2017-05-30 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9579389B2 (en) 2013-02-05 2017-02-28 Purdue Pharma L.P. Methods of preparing tamper resistant pharmaceutical formulations
US9545448B2 (en) 2013-02-05 2017-01-17 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US10517832B2 (en) 2013-03-15 2019-12-31 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US10195152B2 (en) 2013-03-15 2019-02-05 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9616030B2 (en) 2013-03-15 2017-04-11 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
US10449547B2 (en) 2013-11-26 2019-10-22 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
US9913814B2 (en) 2014-05-12 2018-03-13 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
US9855263B2 (en) 2015-04-24 2018-01-02 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US10646485B2 (en) 2016-06-23 2020-05-12 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
US10632201B2 (en) 2017-10-19 2020-04-28 Capsugel Belgium Nv Immediate release abuse deterrent formulations

Also Published As

Publication number Publication date
WO2006082097A1 (fr) 2006-08-10
CN101111232A (zh) 2008-01-23
EP1845955A1 (fr) 2007-10-24
JP2008528653A (ja) 2008-07-31
US10729658B2 (en) 2020-08-04
HK1108370A1 (zh) 2008-05-09
IL185017A0 (en) 2007-12-03
IL185017A (en) 2016-05-31
AR054222A1 (es) 2007-06-13
US20160367486A1 (en) 2016-12-22
EP1845955B1 (fr) 2015-05-27
TWI449540B (en) 2014-08-21
US20160367485A1 (en) 2016-12-22
US20080311197A1 (en) 2008-12-18
CN101111232B (zh) 2012-03-21
US20150283086A1 (en) 2015-10-08
DE102005005449A1 (de) 2006-08-10
JP5265201B2 (ja) 2013-08-14
CA2595979A1 (fr) 2006-08-10
PE20061204A1 (es) 2006-12-15
TW200640500A (en) 2006-12-01
US20150091201A1 (en) 2015-04-02

Similar Documents

Publication Publication Date Title
US10729658B2 (en) Process for the production of an abuse-proofed dosage form
US10130591B2 (en) Abuse-proofed dosage form
US8075872B2 (en) Abuse-proofed dosage form
US20180243237A1 (en) Abuse-proofed dosage form
US20150164811A1 (en) Process for the production of an abuse-proofed dosage form
IL180335A (en) A method of producing a solid dosage form, which is protected against misuse using a planetary gear extrusion machine

Legal Events

Date Code Title Description
AS Assignment

Owner name: GRUNENTHAL GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ARKENAU-MARIC, ELISABETH DR.;BARTHOLOMAUS, JOHANNES DR.;REEL/FRAME:017865/0744

Effective date: 20060421

AS Assignment

Owner name: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT

Free format text: CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS (EXCLUSIVELY LICENSED PATENTS);ASSIGNOR:ENDO PHARMACEUTICALS INC.;REEL/FRAME:025456/0172

Effective date: 20101130

AS Assignment

Owner name: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRA

Free format text: SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS;ASSIGNOR:ENDO PHARMACEUTICALS INC.;REEL/FRAME:026561/0978

Effective date: 20110617

AS Assignment

Owner name: ENDO PHARMACEUTICALS INC., PENNSYLVANIA

Free format text: RELEASE OF SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS RECORDED AT REEL/FRAME 25456/172;ASSIGNOR:JPMORGAN CHASE BANK N.A., AS ADMINISTRATIVE AGENT;REEL/FRAME:026577/0357

Effective date: 20110617

AS Assignment

Owner name: ENDO PHARMACEUTICALS SOLUTIONS INC., PENNSYLVANIA

Free format text: RELEASE OF PATENT SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS;ASSIGNOR:MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT;REEL/FRAME:032380/0157

Effective date: 20140228

AS Assignment

Owner name: ENDO PHARMACEUTICALS INC., PENNSYLVANIA

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF RECEIVING PARTY IN RELEASE OF PATENT SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS PREVIOUSLY RECORDED ON REEL 032380 FRAME 0157. ASSIGNOR(S) HEREBY CONFIRMS THE RELEASE OF SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS.;ASSIGNOR:MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT;REEL/FRAME:032513/0255

Effective date: 20140228

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION